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"My goal is simple. It is a complete understanding of the universe, why it is as it is and 
why it exists at all." 
Stephen Hawking 
 
 
 
 
Abstract 
 
This thesis comprises the design and synthesis of chalcone and chromone derivatives and 
their use in various biological applications, particularly as anticancer agents (targeting 
proteins associated with cancer pathogenesis) and as potential fluorophores for live-cell 
imaging. Conveniently, all structures presented were synthesized from commercially 
available 2´-hydroxyacetophenones. Different synthetic strategies were used to obtain an 
easily accessible chromone scaffold with appropriate handles that allows regioselective 
introduction of various substituents. Structural diversity was accomplished by using 
palladium-mediated reactions for the incorporation of suitable substituents for the 
generation of chromone derivatives that possess different biological activities. 
 
Challenging synthesis provided a series of fluorescent 2,6,8-trisubstituted 3-
hydroxychromone derivatives with high quantum yields and molar extinction coefficients. 
Two of these derivatives were studied as fluorophores in live-cell imaging and showed 
rapid absorption, non-cytotoxic profiles and excellent fluorescent properties in a cellular 
environment.  
 
Synthetic chromone precursors, i.e. chalcones, and related dienones were evaluated as 
antiproliferative agents that interfere with the tubulin-microtubule equilibrium, crucial for 
cellular mitosis. It was shown that several of the synthesized compounds destabilize 
tubulin assembly. However, one of the compounds was instead found to stabilize tubulin 
to the same extent as the known anticancer drug docetaxel, thus representing the first 
chalcone with microtubule stabilizing activity. Molecular docking was used in order to 
theoretically investigate the interactions of the chalcones with -tubulin mainly focusing 
on binding modes, potential interactions and specific binding sites.  
 
Structural-based design and extensive synthesis provided chromone-based derivatives that 
target two different MAP kinases (p38 and MEK1), involved in essential cellular signal 
transduction pathways. The study resulted in a series of highly selective ATP-competitive 
chromone-based p38 inhibitors with IC50 values in the nanomolar range. Among those, 
two derivatives also showed inhibition of p38 signaling in human breast cancer cells. 
Furthermore, molecular docking was used to study potential structural modifications on 
the chromone structure in order to obtain highly potent derivatives that selectively target 
the allosteric pocket on MEK1. Initial studies provided a first generation of non-ATP-
competitive chromone derivatives that prevents the activation of MEK1 with micromolar 
activities. 
 
Keywords: Chalcones, Chromones, Fluorescence, Fluorophore, Cellular imaging, 
Anticancer, Tubulin, Microtubule, Kinase inhibitors, p38, MEK1, Palladium-mediated 
reactions, Molecular modeling, Structure-Activity Relationships. 
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1. General Introduction and Aims of the Thesis 
 
 
 
Proteins are essential components in signal transduction pathways and play crucial roles in 
various possesses within the cell cycle. Consequently, dysregulation of protein function 
related to cell growth, mitosis, proliferation, and apoptosis is strongly associated with 
human cancers. Furthermore, the understanding of cancer pathogenesis on a molecular 
level has improved during the last decades, thus increased the identification of small 
molecular inhibitors that target cancer-specific pathways. As a result, contemporary 
development of novel anticancer agents focuses on compounds that bind to specific 
biological targets instead of non-selective strategies such as radiation or chemotherapy.  
 
This thesis includes the design and synthesis of chalcones and chromone derivatives that 
target mitogen activated protein kinases (proteins that are involved in various processes to 
maintain cell viability) and the tubulin-microtubule equilibrium, which is crucial for 
cellular mitosis. The general aim of the study was to develop efficient synthetic strategies 
to afford structurally diverse chromone derivatives, involving Pd-mediated cross-coupling 
reactions, and to investigate their utility for various applications. The specific objectives 
of the thesis were: 
 
 To use a scaffold methodology in the pursuit to access diverse chromone 
derivatives, which could be decorated by introduction of various substituents using 
palladium mediated C-C coupling reactions. 
 
 To study the spectroscopic properties of 2,6,8-trisubstituted 3-hydroxychromones 
and to investigate their ability as fluorescent probes in a cellular environment using 
live-cell imaging.  
 
 To investigate if synthesized chromone precursors, i.e. chalcones, could interfere 
with the tubulin-microtubule equilibrium which is crucial for cellular mitosis.  
 
 To use molecular docking as a tool for designing chromone-based kinase 
inhibitors/modulators and to evaluate their activity towards two specific kinases, 
p38 and MEK1. 
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2. Background
 
 
 
2.1.  FLAVONOIDS AND RELATED COMPOUNDS 
Flavonoids belong to a large group of abundant plant secondary metabolites, which can 
be found in vascular plants such as ferns, conifers and flowering plants.1-3 These natural 
compounds are generally divided into various classes on the basis of their molecular 
structures including chalcones, flavones, flavanones, flavanols, and anthocyanidins (Figure 
1). Approximately, 4000 varieties of flavonoids have been identified and many of these 
are intense pigments, providing a spectrum of yellow, red and blue colors in flowers, 
fruits and leaves.3-6 Besides their contribution to plant color, flavonoids have several 
pharmacological benefits (e.g. anticancer, anti-inflammatory, anti-allergic, etc.) and are 
known as effective antioxidants, metal chelators and free radical scavengers.3, 7-12 Natural 
and synthetic flavonoids are therefore of considerable interest in the development of 
novel therapeutic agents for various diseases and are generally believed to be non-toxic 
compounds since they are widely distributed in the human diet.2, 5  
 
  
 
Figure 1. Examples of common flavonoids and their derivatives. A, B, and C describe the order of ring 
introduction or ring formation in the synthesis (biosynthesis or synthetic).1, 3, 13  
 
2.1.1  Chalcones 
Chalcones, 1,3-diphenylpropenones (Figure 2), constitute one of the major classes of 
flavonoids with widespread distribution in vegetables, fruits, tea and soy.3, 14 Prehistoric 
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therapeutic applications of chalcones can be associated with the thousand-year old use of 
plants and herbs for the treatment of different medical disorders.15 Contemporary studies 
report a generous variation of significant pharmacological activities of chalcones including 
antiproliferative, antioxidant, anti-inflammatory and anticancer effects.14, 16-18  
 
 
 
Figure 2. The general structure and numbering of chalcones. A and B describe the order of ring 
introduction or ring formation in the synthesis.19  
 
Chalcones are important precursors in the biosynthesis of flavones and flavanones and 
are usually synthesized from acetophenones and benzaldehydes via the Claisen-Schmidt 
condensation, using base in a polar solvent (Figure 3).19-21 In addition, more exotic 
synthetic protocols have been reported, such as the palladium-mediated Suzuki coupling 
between cinnamoyl chloride and phenyl boronic acids or the carbonylative Heck coupling 
with aryl halides and styrenes in the presence of carbon monoxide.22, 23 
 
  
 
Figure 3. Examples of synthetic routes toward chalcones. I) Claisen-Schmidt condensation. II) Suzuki 
cross-coupling. III) Carbonylative Heck reaction.20-23  
 
2.1.2  Chromones 
The chromone ring system, 1-benzopyran-4-one (Figure 4), is the core fragment in several 
flavonoids, such as flavones, flavonols and isoflavones.24 The word chromone can be 
derived from the Greek word chroma, meaning “color”, which indicates that many 
chromone derivatives exhibit a broad variation of colors.  
 
The rigid bicyclic chromone fragment has been classified as a privileged structure in drug 
discovery (i.e. a molecular framework able to provide ligands for diverse receptors), due 
to its use in a wide variety of pharmacologically active compounds such as anticancer, 
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anti-HIV, antibacterial and anti-inflammatory agents.25-34 Several chromone derivatives 
have also been reported to act as kinase inhibitors, to bind to benzodiazepine receptors 
and as efficient agents in the treatment of cystic fibrosis.35-37  
 
 
Figure 4. The general structure and numbering of chromones.24, 38 
 
Although there are a large number of chromone derivatives known for their 
pharmacological properties there are only a few examples that have been or that are used 
as therapeutic agents today. Khellin (Figure 5), extracted from the seeds of the plant 
Ammi visnaga, was the first chromone in clinical practice and it has been used for centuries 
in the Mediterranean area as a diuretic to relieve renal colic.38 Furthermore, around the 
1950s, khellin was used as a smooth muscle relaxant in the treatment of angina pectoris 
and asthma.39 However, present use of khellin as a therapeutic agent focuses on the 
treatment of vitiligo, a pigmentation disorder.40 Other, current medical treatments with 
chromone derivatives can be exemplified by sodium cromoglycate (Lomudal®) used as a 
mast cell stabilizer in allergic rhinitis, asthma and allergic conjunctivitis, diosmin 
(Daflon®) for the treatment of venous diseases and flavoxate a smooth muscle relaxant 
to treat urge incontinence (Figure 5).38, 41-45 
 
  
 
Figure 5. Examples of chromone-based compounds that have been or that are used as pharmaceutical 
agents. Khellin has previously been used for the treatment of angina pectoris and is currently used in the 
treatment of vitiligo. Diosmin is a therapeutic agent for venous diseases, sodium cromoglycate is utilized 
as a mast cell stabilizer in allergic rhinitis, asthma and allergic conjunctivitis and flavoxate is a smooth 
muscle relaxant to treat urge incontinence. 
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Besides their diversity as structural scaffolds, possible to modify to achieve different 
pharmacological activities, several chromone derivatives also exhibit a wide range of 
fluorescent properties. In particular, the 3-hydroxyflavones have been used as hydrogen 
bonding sensors, fluorescent probes for DNA-binding affinity studies and as 
fluorophores for protein labeling and apoptosis.46-49  
 
The most common synthetic routes to the chromone structure occur via a chalcone 
intermediate or via the Baker-Venkataraman rearrangement (Figure 6).24, 50-53 The 
chalcone pathway implicates the base-catalyzed aldol condensation of 2´-
hydroxyacetophenones with aromatic or conjugated aldehydes. The resulting chalcone 
can then be cyclized to a flavone (e.g. in the presence of iodine) or to the corresponding 
3-hydroxyflavone, using alkaline hydrogen peroxide solution, via the Algar-Flynn-
Oyamada (AFO) reaction.54, 55 The Baker-Venkataraman approach involves 
rearrangement of O-acetylated 2´-hydroxyacetophenones to ortho-hydroxy 1,3-diketones 
via enolate formation followed by a base-promoted acyl transfer. The chromone structure 
can then be obtained via acid catalyzed cyclization.24 Several alternative routes to obtain 
chromones and flavones have been reported over the recent years, such as the cyclization 
of alkynyl-ketones (either base promoted or using iodine monochloride) or palladium-
mediated cyclocarbonylation of ortho-iodophenols with terminal acetylenes in the presence 
of carbon monoxide.24, 56, 57  
 
   
 
Figure 6. Common synthetic routes to obtain the chromone structure. I) Synthesis via a chalcone 
intermediate followed by cyclization, e.g. in the presence of iodine or alkaline hydrogen peroxide. II) 
Synthesis via the Baker-Venkataraman rearrangement followed by acid-catalyzed cyclization. 
 
2.2  PALLADIUM-MEDIATED COUPLING REACTIONS 
Transition metals, such as palladium, copper, nickel, iron and rhodium play an important 
role in organic synthesis since they can catalyze the formation of new bonds, especially C-
C bonds. A large number of transition metal-mediated reactions have been reported 
during the past decades and many of these have become essential in the synthesis of 
complex organic molecules including biologically active compounds such as natural 
products and steroids.24, 58, 59  
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This thesis includes introduction of various substituents on the chromone scaffold via 
various palladium-mediated coupling reactions, in particular the Heck, Sonogashira, 
Suzuki and Buchwald-Hartwig reactions, which will be discussed further in the following 
chapters.  
 
2.2.1  Palladium-catalyzed couplings in organic synthesis 
Palladium is by far the most important and frequently used transition metal in organic 
coupling reactions.60 Thus, the 2010 Nobel Prize in chemistry was awarded to Richard F. 
Heck, Ei-ichi Negishi and Akira Suzuki for the development of palladium-catalyzed cross-
coupling reactions in organic synthesis.61 Well-known coupling reactions with palladium 
as a catalyst are illustrated in Figure 7. 
 
  
 
Figure 7. Examples of common palladium-catalyzed reactions in organic synthesis.24 
 
The general mechanism for Pd-catalyzed cross-coupling reactions with organometallic 
reagents (e.g. the Sonogashira, Negishi, Stille and Suzuki reactions) involves three stages: 
oxidative addition, transmetallation and reductive elimination (Figure 8). The cycle starts 
with a zerovalent catalyst, Pd(0), generally constructed of palladium and ligands such as 
phosphines, amines or N-heterocyclic carbenes. However, Pd(II) complexes are 
frequently used as pre-catalysts since they are generally more stable than the Pd (0) 
species. Nevertheless, these pre-catalysts need to be reduced to Pd(0), which can be done 
as an initial step in situ, before the catalytic cycle can begin. The oxidative addition step 
involves insertion of Pd(0) into the R-X bond along with a simultaneous oxidation of 
Pd(0) to Pd(II). In terms of chemoselectivity and relative rate, the reaction is dependent 
on X according to the trend: X = I > Br  OTf >> Cl >>F. Subsequent transmetallation 
with a nucleophilic organometallic reagent, such as copper acetylides or boronic acids, 
involves transfer of the R-group to palladium with displacement of X. In the last step, the 
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unstable intermediate is subjected to reductive elimination creating a carbon-carbon bond 
and regeneration of the palladium(0) complex.58, 59  
 
  
 
Figure 8. General catalytic cycle for palladium-mediated cross-coupling reactions.58 
 
The Heck reaction, with olefins and alkyl or aryl halides, does not involve organometallic 
reagents, which results in a slightly different mechanism than the one described above.62-65 
As illustrated in Figure 9, the olefin forms a -complex with the palladium catalyst after 
the oxidative addition step. Subsequently, the R-group on palladium migrates to one of 
the olefin carbons at the same time as the palladium gets attached via a σ-bond to the 
other carbon. The generated alkylpalladium intermediate then undergoes a -hydride 
elimination giving an R-substituted olefin product and a hydridopalladium halide. Finally, 
the palladium complex undergoes a reductive elimination in the presence of base to 
regenerate the palladium(0) catalyst.58, 59  
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Figure 9. General catalytic cycle for the Heck reaction.58 
 
2.3  MOLECULAR MODELING IN DRUG DISCOVERY 
The term molecular modeling includes theoretical methods and computational 
methodologies that are used to mimic or predict the behavior of molecules and molecular 
systems. These methods usually involve molecular mechanics, quantum mechanics, 
conformation analysis, and molecular dynamics.66 Molecular modeling technologies have 
mainly been developed during the past decades, due to the development of fast 
computers, and are today essential tools in drug development used for protein structure 
determination, sequence analysis, protein folding, homology modeling, docking studies 
and pharmacophore determination. 
 
Currently, two major modeling strategies are used for the design of new drugs and these 
are generally based on whether three-dimensional (3D) structures of the biological targets 
or related proteins are available or not:  
Structure-based (direct) drug design is generally performed using a known 3D 
structure of a specific biological target (e.g. a receptor or an enzyme), information that is 
usually provided by techniques such as NMR spectroscopy or X-ray crystallography.67, 68 
Alternatively, if the 3D structure of a specific target is unavailable, it is possible to 
generate a homology model based on a related protein. Three-dimensional data of target 
proteins bound to known inhibitors or antagonists provide invaluable information that 
allows active site determination, identification of important binding interactions within 
the active site and further possibilities for docking of other compounds.  
Ligand-based (indirect) drug design is generally used if the 3D structure of a 
particular target is unavailable. This strategy relies on known active compounds that bind 
to the biological target of interest and that are complementary with a hypothetical active 
10 
 
site.68 These together with known inactive compounds can be used to create a 
pharmacophore model that defines essential structural features for binding and activity.69 
In addition, incorporating inactive compounds into the model can give information about 
forbidden volumes with the aim to constrain the prototype. Furthermore, known ligands 
can be used for the development of a target specific quantitative structure-activity 
relationship (QSAR) model that uses molecular descriptors as numerical representations 
of chemical structures. Thus, physicochemical properties of compounds are correlated 
with their pharmacological activity and the calculated mathematical relationship can 
predict the activity of novel compounds. 
 
2.3.1  Molecular docking 
Molecular docking is commonly used in the field of drug design to predict the binding of 
small molecules to biological protein targets. This method gives the possibility to study an 
active site in detail and can be used for hit identification, virtual screening, binding mode 
determination, and lead optimization. Generally, the docking methodology is used to fit a 
compound into an artificial model or to a known three-dimensional binding site, which 
can be utilized to explore ligand conformation, orientation and feasible molecular 
interactions such as hydrogen bonding and hydrophobic interactions. Thus, molecular 
docking is a powerful tool for the design of ligands toward a specific protein target. 
Although, molecular docking is a useful tool in drug design it should be used with 
common sense since it comprise artificial models of complex structures with high 
flexibility and dynamics.  
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3. 3-Hydroxychromone Derivatives as 
Fluorophores for Live-Cell Imaging (Paper I) 
 
 
 
3.1  INTRODUCTION 
 
3.1.1  Fluorescence spectroscopy 
Fluorescence is a photoluminescence phenomenon in which spontaneous emission of 
electromagnetic radiation normally occurs within a few nanoseconds after an atom or a 
molecule is being excited to a higher state.70, 71 Structural features (generally in 
polyaromatic hydrocarbons or heterocycles) that are responsible for the fluorescent 
mechanism are called fluorophores, and molecules that exhibit fluorescence properties are 
commonly designated as fluorophores or fluorescent dyes.72  
 
  
 
Figure 10. Jablonski diagram.70 Following photon absorption, a fluorophore is generally excited from its 
singlet ground electronic state (S0) to a higher energy level such as S1 or S2. Subsequently, the fluorophore 
relaxes to the ground state (S0), via fluorescence or phosphorescence, by emitting a photon.  
 
The photophysical relationship between absorption and emission is usually described by 
the Jablonski diagram, which illustrates the electronic states of a molecule and the 
transitions between them (Figure 10). Following photon absorption, a fluorophore is 
generally excited from its singlet ground electronic state (S0) to a higher energy level such 
as S1 or S2. In each electronic state, the fluorophore can exist in a number of vibrational 
levels. In the excited state, the fluorophore is subjected to collisions with the surrounding 
molecules, which results in energy loss as it descends the vibrational ladder to the lowest 
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level of that state. Further deactivation via internal conversion to lower lying excited 
states and vibrational relaxation to the lowest vibrational level of S1 then occurs. 
Subsequently, the fluorophore relaxes to the ground state (S0) via the fluorescence 
pathway by emitting a photon. The difference in energy between the maxima of the 
spectral absorption and emission bands is commonly referred to as the Stokes shift, 
which is an effect of rearrangements of the solvent around the fluorophore. Additionally, 
in phosphorescence, the photon emission can occur for longer periods as a result of spin 
conversion to a forbidden triplet state (T1) via an intersystem crossing process followed 
by further relaxation in another spin-forbidden process from T1 to S0.70, 71  
 
The efficiency of the fluorescence process is generally described by the quantum yield 
(ΦF), defined as the ratio of the number of photons emitted to the number of photons 
absorbed. The maximum fluorescence quantum yield is 1.0 (100%), which can be reached 
if the number of photons absorbed is equal to the number of photons emitted. The 
fluorescence intensity can be decreased by various quenching mechanisms such as contact 
with collisional quenchers (e.g. molecular oxygen, halogens and specific amines) and 
complex formation with a molecule that generates a nonfluorescent complex.70  
 
Fluorescence methodologies are used in a large range of valuable biochemical 
applications, including structural determination of proteins, DNA sequencing, medical 
diagnostics, and organelle staining in living cells.70 A large number of fluorophores have 
been developed and discovered during the last decades, e.g. fluorescein, rhodamine and 
quinine (Figure 11).72 
 
 
 
Figure 11. Fluorescein, rhodamine and quinine are examples of fluorescent dyes with applicable 
photophysical properties, such as high quantum yields (e.g. Fluorescein = 0.92 and Quinine = 0.55).72-74 
 
3.1.2  Multiphoton excitation and fluorescent microscopy 
Besides one-photon excitation, fluorophores can reach the excited state by simultaneous 
absorption of two-photons or more, known as multiphoton excitation (MPE).70 This can 
be achieved by using a high energy pulsed laser, which provides a high stream of photons. 
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MPE, in particular two-photon excitation (2PE), is predominantly used in fluorescence 
microscopy for the investigation of biological systems, due to several important 
advantages over one-photon excitation (1PE) techniques. 2PE is achieved by using longer 
wavelengths, i.e. infrared light, to avoid the much stronger single-photon absorption of 
the fluorophore and to decrease effects of light scattering by the cell content. 2PE 
microscopy increases the cell viability and allows the use of an optimal excitation 
wavelength. Moreover, almost all fluorophores are photobleached upon continuous 
illumination, especially in fluorescence microscopy where the light intensities are high. 
Thus, the use of 2PE minimizes photobleaching and phototoxicity, which are limiting 
factors in fluorescence microscopy of living cells and tissues.70, 75  
 
3.1.3 Fluorescent characteristics and applications of 3-hydroxychromone 
derivatives  
In 1979, Sengupta and Kasha reported the characteristic dual fluorescent behavior of 3-
hydroxyflavones.76 Upon excitation, the 3-hydroxychromone fluorophore exhibits two 
well-separated emission bands, originating from the excited normal species (N*) and the 
phototautomer (T*) formed via an excited state intramolecular proton transfer (ESIPT) 
(Figure 12).77, 78  
 
 
 
Figure 12. The dual fluorescent behavior of 3-hydroxychromones represented in an energy diagram.76 
Upon excitation, the normal excited species (N*) undergoes an excited intramolecular proton transfer 
(ESIPT) to give the excited tautomer (T*). The R-group in the figure is generally an aromatic moiety, e.g. 
phenyl. 
 
Due to their characteristic fluorescence behavior, 3-hydroxychromone derivatives have 
been used as biosensors, hydrogen bonding sensors, and as fluorescent probes for 
dipotential (ΨD) measurements in lipid bilayers.79-85 They have also been used for studies 
of DNA interactions and as photochemical dyes for protein labeling and apoptosis.47, 86-88 
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The photophysical behavior of 3-hydroxychromones has been carefully studied and 
efforts have been made to develop derivatives with improved and exceptional fluorescent 
properties. For example, a strong electron donating substituent in the para-position on the 
B-phenyl ring, such as in 2-(4-diethylaminophenyl)-3-hydroxychromones, have shown to 
be beneficial for the fluorescent behavior (Figure 13).78, 89 The electron-rich diethylamine 
functionality contributes to a significant change in the electron distribution resulting in 
derivatives with high quantum yields (F 0.5). It has also been proposed that the S1 state 
for 2-(4-diethylaminophenyl)-3-hydroxychromones is represented by a zwitterionic 
excited species, which is induced via charge transfer (Figure 13).89 
 
 
 
Figure 13. 2-(4-Diethylaminophenyl)-3-hydroxychromones exhibit interesting fluorescence properties. In 
addition to the ESIPT mechanism, they are able to adopt a zwitterionic excited state, which is induced via 
charge transfer.89 
 
3.2  RESULTS AND DISCUSSION 
In a project aimed at the development of novel chromone-based peptidomimetics, we 
came across a series of fluorescent 3-hydroxychromone derivatives with electron 
withdrawing and donating aromatic or conjugated substituents in the 2-position.90, 91 
Thus, we wanted to characterize the fluorescent properties of these derivatives and 
investigate how various substituents in the 2-position affect the ESIPT process, the 
absorption/emission maxima, and the fluorescence quantum yields. One aim was to 
extend the series with a few 2-(4-dietylaminophenyl)-3-hydroxychromone derivatives, due 
to their known and interesting fluorescence properties.89 In addition, we also wanted to 
explore the utility of 3-hydroxychromone derivatives as fluorophores for live-cell imaging. 
However, the use of living cells implicates a number of important aspects that need to be 
taken into consideration such as permeability, solubility and UV-exposure. Considering 
this, the idea was to extend the conjugation of the chromone chromophore and to 
enhance the polarity by introducing an aminopropyl group to the A-ring. We also thought 
that the amine functionality could be used as a handle for the attachment of other 
compounds, i.e. probing, for various applications within the field of bioimaging. 
 
3.2.1  Synthesis of 2,6,8-trisubstituted 3-hydroxychromone derivatives 
In 2006, Dahlén et al. reported a scaffold approach toward 3,6,8-trisubstituted flavones 
using 3´-bromo-5´-chloro-2´-hydroxyacetophenone (1) as starting material.91 This flavone 
scaffold enables regioselective introduction of substituents at the given positions as well 
as construction of a series of structural diverse derivatives that could be used for various 
applications. Moreover, the synthetic route also involves efficient generation of 
fluorescent 3-hydroxychromone derivatives with various aromatic or conjugated 
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substituents in the 2-position. Consequently, we wanted to use this scaffold methodology 
in the present study.  
 
3.2.1.1  Synthesis of the chromone scaffold 
Chalcones 3-7 and the dienone 8 were prepared via a Claisen-Schmidt condensation, from 
commercially available 3´-bromo-5´-chloro-2´-hydroxyacetophenone 1 and various 
aromatic or conjugated aldehydes with electron-deficient or donating properties, using 
KOH in EtOH (Scheme 1).90, 91 Compounds 3-8 were obtained in high yields (90-98%), 
after efficient recrystallization from EtOH. Initially, it was anticipated that the same 
reaction conditions also could be used to provide the diethylamino derivatives (Figure 
13). However, no product could be traced or isolated when using 4-
diethylaminobenzaldehyde in the condensation reaction. A possible explanation for this 
could be that, the strong electron donating diethylamino group in the para-position makes 
the aldehyde less electrophilic, which aggravates the essential nucleophilic attack at the 
carbonyl carbon. Similar protocols but with other bases were attempted, such as Ba(OH)2 
in MeOH or NaOMe in DMF, but disappointedly without any product formation.92, 93  
 
 
 
Scheme 1. Synthesis of dihalogenated 3-hydroxychromone derivatives 12-20. Reagents and conditions: (a) 
the appropriate aldehyde, KOH, EtOH, 50 C  rt, overnight; (b) 4-diethylaminobenzaldehyde, aqueous 
NaOH (60%), MeOH, rt, overnight; (c) NaOH, aqueous H2O2 (30%), MeOH/THF (1:1), 0 C  rt, 
overnight. aNot determined due to purification problems. 
 
Due to problems in the synthesis of the diethylamino derivatives, a new synthetic strategy 
was developed. According to the new approach, based on the retrosynthetic analysis 
illustrated in Figure 14, the diethylamino containing compounds could be provided from 
the corresponding 4-nitrophenyl derivatives with the aim to later convert the nitro group 
to diethylamine via chemoselective reduction and subsequent N-diethylation. Chalcone 9 
was obtained using the Claisen-Schmidt reaction conditions described above (Scheme 1). 
However, the product was difficult to purify, mainly due to severe solubility problems in 
an array of solvents (polar and non-polar). Thus, the crude product of 9 was used in the 
next reaction step without any further purification. 
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Figure 14. Retrosynthetic analysis for the synthesis of 2-(4-diethylaminophenyl)-3-hydroxychromones via 
the corresponding nitro derivatives. 
 
Chalcones, 3-7 and 9, and the dienone 8 were cyclized to the corresponding 3-
hydroxychromones 12-18 via the Algar-Flynn-Oyamada (AFO) reaction, using aqueous 
hydrogen peroxide (30%) and 4M NaOH in a 1:1 mixture of THF and MeOH (Scheme 
1).90, 91 Subsequent recrystallization from EtOH gave the chromones 12-18 in moderate to 
high yields (43-98%). However, once again we faced solubility problems with the nitro 
derivative 18. Hence, the crude product of 18 was used in the next reaction step without 
any further purification. 
 
Next, the focus was directed towards the preparation of new 3-hydroxychromone 
derivatives with applicable fluorescence properties. Compound 13 and 18 were selected 
for further synthesis, since they possess groups that are or that easily can be converted 
into electron-rich moieties. To avoid purifications problems on silica the hydroxyl 
functionality in the 3-position of 13 and 18 was acetylated. Two similar protocols, with 
different solvents, were used for the protection step (Scheme 2). Compound 13 was 
treated with acetyl chloride and triethylamine in dichloromethane, whereas the protection 
of 18 was conducted using the same acetylation agent and base in DMF. The protocols 
gave 21 and 22 in moderate or high yields, respectively.94 However, the latter was 
preferable since the convenient work up, addition of water, gave precipitation of the pure 
product, which could be isolated after filtration. 
 
After dealing with problems related to solubility and purification, the acetylated nitro 
derivative 22 was finally obtained (as described above). However, attempts to perform the 
subsequent Sonogashira reaction in the 8-position of 22 failed and only the starting 
material could be regenerated (not shown). Consequently, no further synthetic efforts 
were made with the nitro derivatives. Hence, the focus was ones again to synthesize the 2-
(4-diethylaminophenyl)-3-hydroxychromone derivatives by using the 4-diethylamino-
benzaldehyde. New attempts, with stronger alkaline conditions, were performed. 
Consequently, the diethylamino derivatives 10-11 were successfully obtained from 
dihalogenated 2´-hydroxyacetophenones 1-2, using aqueous sodium hydroxide (60%) in 
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MeOH (Scheme 1).92 Furthermore, the corresponding 3-hydroxychromone derivatives 
19-20 were obtained by the AFO reaction using the same conditions as described above. 
 
The 2-(4-diethylaminophenyl)-3-hydroxychromones 19-20 were first successfully 
protected as acetyl esters using acetyl chloride and triethylamine in DMF. However, the 
subsequent Sonogashira cross-coupling in the 8-position (described below) gave products 
that decomposed (ring-opened) on silica gel during the purification process. Instead, 19-
20 were protected as the more stable isobutyric esters 23-24, using isobutyric anhydride in 
pyridine (Scheme 2). 
  
  
 
Scheme 2. Protection of the hydroxyl functionality in the 3-position to obtain 21-24. Reagents and 
conditions: (a) acetyl chloride, Et3N, dichloromethane, rt, overnight or acetyl chloride, Et3N, DMF, rt, 24 
h; (b) isobutyric anhydride, pyridine, rt, 18-36 h. aCalculated yield over three steps, starting from 
compound 1 (Scheme 1). 
 
3.2.1.2  Synthesis of the final compounds via the Sonogashira reaction 
The general Sonogashira reaction was first reported in 1975, and involves cross-coupling 
between terminal alkynes and aryl or alkenyl halides or triflates in the presence of a Pd-
catalyst, a base and generally copper iodide as a co-catalyst.95, 96 Furthermore, the use of 
microwave assisted organic synthesis (MAOS) in transition-metal-catalyzed reactions, 
such as the construction of C-C bonds, has shown several beneficial aspects over 
conventional heating.97, 98 MAOS generates efficient internal heating in sealed vessels, 
which allows high temperature and high pressure. Accordingly, organic reactions can be 
accelerated giving enhanced reaction rates and reduced reaction times.  
 
Microwave-assisted Pd-couplings, in particular on the chromone ring system, have 
frequently been used and studied in our research group.90, 99, 100 Hence, a microwave-
assisted Sonogashira reaction was used for the regioselective introduction of N-Boc-
protected propargylamines in the 8-position of the chromone scaffold. Compounds 25-27 
were prepared from 21 and 23-24, in a microwave cavity at 120 C, in the presence of N-
Boc-propargylamine, PdCl2P(Ph3)2, triethylamine and copper iodide in THF (Scheme 3). 
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Two equivalents of the terminal alkyne were used for the coupling of 21 to give 25, 
whereas four equivalents were required for the diethylamino derivatives 23 and 24 to 
obtain the products 26-27. As expected, the coupling of the dibromo derivative 24 also 
resulted in the dicoupled product, giving a lower yield of the monocoupled derivative 27 
(16%). However, the dicoupled derivative was not completely characterized due to 
purification problems. Compound 25 was purified by column chromatography, on silica 
gel, whereas the diethylamino derivatives 26-27 were purified on neutral aluminum oxide, 
to avoid decomposition during the purification process. Furthermore, two important 
aspects were noticed for the Sonogashira reaction. First, 120 C is an optimal reaction 
temperature, since higher temperature results in Boc-deprotection and lower gives 
decreased yields. Secondly, the addition order of the reagents is crucial, the products 
could only be obtained when the co-catalyst (CuI) was added last, a few seconds prior to 
vessel capping. 
 
 
 
Scheme 3. Synthesis of the final compounds 29-31 via the Sonogashira reaction. Reagents and conditions: 
(a) N-Boc-propargylamine, PdCl2(PPh3)2, NEt3, CuI, THF, 120 C, 20 min, microwave heating; (b) 
NaOMe, MeOH, rt, 5h; (c) HCl, MeOH, rt, 6-40 h. 
 
Compound 29 was obtained by using two consecutive deprotecting protocols. The acetyl 
ester in 25 was hydrolyzed with NaOMe in MeOH, to produce the corresponding 3-
hydroxychromone derivative 28 (Scheme 3). Furthermore, deprotection of the Boc-group 
in 28 was performed by HCl in MeOH to give the primary amine 29. However, it was 
later found that the first deprotection step with NaOMe was unnecessary since the target 
compounds 30-31 could be obtained directly from 26-27 using acidic conditions. Thus, 
dual deprotection of 26-27, using HCl in MeOH, gave the HCl salts of the amines 30-31 
in high yields (82 and 99%, respectively).  
19 
 
 
Additionally, in order to study the difference in fluorescence properties between 
conjugated and non-conjugated substituents in the 8-position, the alkyne in 25 was 
reduced to the corresponding alkyl derivative (32). The conversion was performed by 
catalytic hydrogenation over Pd/C (5%) in a 1:1 mixture of dioxane/MeOH (Scheme 4). 
As a consequence of the reducing conditions, the acetyl ester in the 3-position was 
simultaneously cleaved off via hydrogenolysis giving 32 in 80% yield.  
 
 
 
Scheme 4. Conversion of the alkyne in 25 to the corresponding alkyl 32. Reagents and conditions: (a) H2, 
Pd/C (5%), MeOH/dioxane (1:1), room temperature, 15 h. 
 
3.2.2  Photophysical characterization 
The synthesized 3-hydroxychromones, 12-17, 19-20, 29-32, with electron-withdrawing and 
donating aromatic or conjugated substituents in the 2-position and the protected 2-(4-
diethylaminophenyl)-3-isobutyroxychromone derivatives, 23-24 and 26-27, were 
characterized for their photophysical properties (Table 1). All measurements were 
performed in ethanol solutions (95%) due to a favorable solubility profile. Absorption 
and emission spectra of the compounds were collected using highly diluted samples of 
unknown concentrations. The majority of the 3-hydroxychromone derivatives, 12-17, 29 
and 32, showed low energy absorption maxima centered around 360 nm and two well-
separated emission maxima originating from the normal excited species (N*) and the 
excited phototautomer (T*) centered at ~ 440 nm and ~ 555 nm, respectively (Figure 15). 
As expected, the 2-(4-dietylaminophenyl)chromone derivatives, 19-20 and 30-31, shifted 
the absorption (~ 440 nm) and emission maxima to longer wavelengths (red-shift) and 
gave a single defined emission maximum, representing the excited normal species (N*), 
centered at ~ 565 nm (Figure 16). The red-shifted single emission band for 19-20 and 30-
31 is an effect when using a strongly polar and protic solvent, such as ethanol, due to 
strong charge transfer properties, perturbation and solvatochromism.89 In detail, solvent 
stabilization of zwitterionic species in the excited charge transfer state, with a positive 
charge on the 4´-diethylamino group and a negative charge on the carbonyl oxygen, 
possess lower energy than T* and are therefore more energetically favorable than ESIPT. 
In contrast, it has been demonstrated that decreasing the solvent polarity from ethanol to 
hexane results in a significantly increased formation of the excited tautomer (T*).93, 101 In 
other words, the dual emission for 2-(4-diethylaminophenyl)-3-hydroxychromone 
derivatives is strongly dependent on the polarity of the solvent.  
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Table 1. Photophysical data of 2,6,8-trisubstituted 3-hydroxychromones 12-17, 19-20 and 29-32, and 
2,6,8-trisubstituted 3-isobutyroxychromones 23-24 and 26-27.a 
 
 
 
Compd R2 R3 R6 R8 λabs 
(nm) 
λem 
(nm)b 
ε  
(M-1 
cm-1) 
ΦF 
      N* T*   
12 Phenyl OH Cl Br 355 435 550 12000 0.07 
13 4-MeO-Ph OH Cl Br 370 446 554 23000 0.06 
14 2-Thienyl OH Cl Br 372 438 560 19000 0.09 
15 3-Thienyl OH Cl Br 358 434 548 17000 0.13 
16 4-CF3-Ph OH Cl Br 354 436 553 14000 0.03 
17 CH=CHPh OH Cl Br 381 446 544 12000 0.05 
19 4-NEt2-Ph OH Cl Br 438 564  27000 0.43 
20 4-NEt2-Ph OH Br Br 439 565  27000 0.42 
23 4-NEt2-Ph OCOCH(CH3)2 Cl Br 417 556  36000 0.04 
24 4-NEt2-Ph OCOCH(CH3)2 Br Br 418 560  32000 0.06 
26 4-NEt2-Ph OCOCH(CH3)2 Cl C≡CCH2NHBoc 420 554  33000 0.12 
27 4-NEt2-Ph OCOCH(CH3)2 Br C≡CCH2NHBoc 420 553  30000 0.12 
29 4-MeO-Ph OH Cl C≡CCH2NH2 372 444 556 14000 0.10 
30 4-NEt2-Ph OH Cl C≡CCH2NH2 441 568  21000 0.49 
31 4-NEt2-Ph OH Br C≡CCH2NH2 443 570  18000 0.48 
32 4-MeO-Ph OH Cl (CH2)3NHBoc 362 434 542 16000 0.07 
aPhotophysical data measured in 95% ethanol. bEmission values originating from the normal excited form  
(N*) and the phototautomer (T*), which is formed via an excited state intramolecular proton transfer 
(ESIPT). 
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However, the excitation of the 2-(4-diethylaminophenyl)-3-hydroxychromone derivatives 
show lower solvent polarity dependence compared to Nile Red, a known solvatochromic 
dye, while the emission shows higher solvent polarity dependence.102, 103 Furthermore, the 
emission maximum for 4´-diethylamino-3-hydroxyflavone has been reported to have 
much shorter wavelength (~ 505 nm) than those observed for 19-20 and 30-31.89 
However, in studies where electron-withdrawing groups (e.g. methoxycarbonylvinyl) are 
attached to the 7-position of the chromone both the absorption and emission maxima are 
significantly red-shifted, therefore the shift to longer wavelengths observed for our 
compounds was expected since Cl, Br and 3-amino-1-propynyl groups are all electron 
withdrawing.104  
 
 
Figure 15. Emission spectra for the 3-hydroxychromone derivatives 12-15. These derivatives exhibit dual 
fluorescence behavior giving two well-separated emission maxima originating from the normal excited 
species (N*) and the phototautomer (T*). 
 
The fluorescent quantum yields (F) were measured relative to fluorescein or quinine 
sulfate with an excitation wavelength of 465 or 360 nm, respectively. The results showed 
that the quantum yield is highly dependent on the electronic properties of the substituent 
in the 2-position of the 3-hydroxychromone system (Table 1). For example, the 
introduction of a strong electron withdrawing 4´-CF3-phenyl group, as in 16, results in the 
lowest quantum efficiency (F = 0.03) among all the derivatives. However, the trend is 
not completely obvious when comparing 12-17, showing increasing F values (between 
F = 0.03-0.13) in the series 4´-CF3-Ph  CH=CHPh  4´-MeO-Ph  phenyl  2´-thienyl 
 3´-thienyl. On the other hand, introduction of a 4´-diethylaminophenyl substituent, as 
in 19-20, increases the quantum yield dramatically (ΦF = 0.42-0.43) due to the strong 
electron donating properties from the para-diethylamino group thus facilitating charge 
transfer and dielectric stabilization. The para-positioned methoxy group, as in 13, does not 
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show the same electron donating ability leading to a considerably lower quantum yield 
(ΦF = 0.06). In comparison with the 8-bromo-analogs 13 and 19-20, the introduction of 
an electron-withdrawing 3-amino-1-propynyl substituent in the 8-position, as in 29-31, 
resulted in only minor variations in absorption and emission values and in quantum 
yields. Similar results were also observed for the reduced 3-(tert-butoxy-
carbonylamino)propyl derivative 32.  
 
 
Figure 16. Emission spectra for the 2-(4-dietylaminophenyl)chromone derivatives 19-20 and 30-31. These 
compounds exhibit single defined emission maxima (N*) in ethanol due to strong charge transfer 
properties, perturbation and solvatochromism.  
 
To investigate the importance of the free hydroxyl group in the 3-position and its ability 
to undergo ESIPT for the fluorescence capacity, the protected 3-isobutyroxychromone 
derivatives, 23-24 and 26-27, were also photophysically characterized. These derivatives 
are not able to exhibit dual fluorescence. Thus, as expected, the spectra of 23-24 and 26-
27 exhibit one single defined emission band, assigned to the normal excited species (N*), 
centered at 555 nm. Moreover, the similarity in emission maxima compared with the 
unprotected derivatives, 19-20 and 30-31, confirm that the single emission band for the 2-
(4-dietylaminophenyl)chromone derivatives originates from the N* state. In addition, 
when comparing 23-24 and 26-27 with the unprotected derivatives 19-20 and 30-31, we 
observed higher molecular extinction coefficients and dramatically decreased quantum 
yields (from ΦF of 0.4-0.5 to 0.1) (Table 1). In spite of this, the results indicate that 
esterification of the 3-hydroxyl group results in compounds with acceptable and useful 
fluorescence properties. 
 
Extinction coefficients () were determined from samples with known concentrations of 
test compounds (typically 20 M). All the 3-hydroxychromone derivatives, 12-17, 19-20, 
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29-32 showed high extinction coefficient values (  12,000 M-1 cm-1), with the highest 
values for 19-20 ( = 27,000 M-1 cm-1). However, as mentioned above, the difference in 
quantum yields between the derivatives is more pronounced. Interestingly, the extinction 
coefficients for the 3-isobutyroxychromone derivatives 23-24 and 26-27 were even higher 
( = 30,000-36,000 M-1 cm-1) than those for 19-20 ( = 27,000 M-1 cm-1), but again the 
quantum yields are much lower. Thus, the 3-hydroxy group is important for obtaining 
high quantum yields, but it is evidentially possible to use esterified derivatives for 
fluorescence studies. 
 
With the aim to use 3-hydroxychromones as fluorophores for live-cell imaging, the 
fluorescence quantum yields of the more hydrophilic 30 and 31 were also measured in 
water. Interestingly, the quantum yield for these derivatives was found to be zero. 
However, this kind of observation has been reported earlier. It has been shown that the 
quantum yield for 4´-diethylamino-3-hydroxyflavones in ethyl acetate decreases with the 
addition of water, and becomes completely quenched in pure water.105, 106 In contrast, 2-
(2-furyl)- and 2-(2-benzofuryl)-3-hydroxychromones have shown ESIPT in water and the 
increase in quantum yields was especially pronounced for derivatives containing an 
electron-donating substituent in the 7-position.106 However, we reasoned that the 
quenching in water for 30 and 31 could be used as an advantage since they would not be 
detectable in a hydrophilic cellular environment but instead exhibit fluorescence 
properties when moving into more hydrophobic areas, e.g. into a hydrophobic active site, 
a hydrophobic receptor binding pocket or into membrane structures. Theoretically, these 
derivatives could be used as indicators for protein interactions and receptor binding 
studies.  
 
3.2.3  Live-cell imaging of compounds 29 and 30, using 2PE microscopy 
In 2004, Shynkar et al. reported the use of 3-hydroxychromones as fluorescent probes for 
live-cell imaging in plasma membranes.85, 107 Thus, we wanted to investigate the potential 
use of our synthesized compounds in such applications and observe their photochemical 
and biochemical behavior in terms of photostability, transport, permeability, localization 
and distribution in a cellular environment. 
 
Compounds 29 and 30 were dissolved in a minimum amount of DMSO to avoid 
cytotoxicity and cell leakage. The DMSO solutions were further diluted (with Hank’s 
balanced salt solution, HBSS) to generate appropriate concentrations (0.5 mM and 0.1 
mM, respectively). A monolayer of HeLa cells (in 1.8 mL cell medium) were stained with 
solutions of either 29 or 30 at 37 C and the viability of the cells was monitored during 
approximately one hour. The fluorescence was observed by multi-photon laser scanning 
microscopy in the 500-700 nm region by using 2PE excitation at 750 and 900 nm, 
respectively.108 Images of the cells were collected at regular and increasingly time intervals.  
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Figure 17. Live-cell imaging of HeLa cells, stained with 29 (A and C) or 30 (B and D), using two-photon 
excitation (2PE). Panels A and B: Single planes, larger field of view (215215 m2), after approximately 20 
minutes. Panels C and D: Uptake after 12 min, single planes, (7474 m2) from the middle of 9 m thick 
z stacks. The images have been modified for clarity (negative picture mode). 
 
Figure 17 depicts the cellular uptake of 29 and 30 at two different time points. Figure 17A 
and B, show larger fields after approximately 20 min, whereas Figure 17C and D display 
enlarged fields with a few cells and their uptake after 12 min. The imaging revealed rapid 
penetration with an observed cellular uptake within a minute after the incubation (data 
not shown). Both compounds are accumulated between the cellular membrane and the 
nucleolus and they seem to be taken up by endosomal structures, indicated by the bright 
punctuate structures in the images, and by weaker fluorescent membrane network 
structures that resemble the endoplasmic reticulum. This observation suggests that the 
cellular uptake occurs via an active endocytotic mechanism. Thus, additional experiments 
were conducted in order to investigate the transport mechanism and to confirm our 
hypothesis. HeLa cells were fixed and stained with either 29 or 30 at 4 C. The 
experiments showed no cellular uptake at the given temperature, which satisfyingly 
support the assumption regarding endocytosis as the pivotal transport mechanism since 
endocytosis cannot occur at low temperatures.109 Moreover, cross-section images through 
the z-stacks established the fact that the compounds are located inside the cell and not in 
the cellular membrane. Additionally, there was no indication of cytotoxic effects after 
fluorophore incubation for approximately two hours. The significant difference in 
25 
 
photophysical properties between 29 and 30, such as extinction coefficients () (14000 vs. 
21000 M-1 cm-1), quantum yields (F) (0.10 vs. 0.49) and cross-section values (0.13 vs. 12 
GM),110 could easily be visualized during the experiments. Despite the fact, that the added 
concentration of 30 was lower than 29 (0.01 mM and 0.05 mM, respectively). The 
intensity of 30 is clearly stronger than 29, however both compounds exhibit interesting 
and adaptable photophysical properties that could be used for various applications within 
the field of fluorescence microscopy. 
 
3.3  CONCLUSIONS 
In conclusion, the work presented in this chapter demonstrates that multifunctionalized 
3-hydroxychromone derivatives constitute a new promising class of fluorophores useful 
for live-cell imaging. Two of the synthesized derivatives, 29 and 30, with adequate and 
high fluorescence quantum yields (0.10 and 0.49, respectively) show rapid permeability 
and non-toxic profiles in living cells. The fluorescence microscopy studies revealed that 
the derivatives are accumulated between the cellular membrane and the nucleolus, and 
that the cellular uptake probably occurs via endocytosis. The fluorescence quenching 
observed in water for 30 and 31 gives opportunities to use these derivatives as probes for 
receptor-binding studies, i.e. to study the movement from hydrophilic areas into more 
hydrophobic compartments. Further studies of 3-hydroxychromones as fluorophores for 
live-cell imaging could involve applications such as protein labeling, examination of 
specific binding interactions to target proteins, and/or the cellular localization coupled to 
other compounds targeted for specific organelles. Alternatively, due to the designation as 
privileged structures, it could be interesting to combine biological activity and fluorescent 
properties, for example, to design fluorescent chromone-based enzyme inhibitors and to 
follow their uptake and accumulation in living cells by using fluorescence microscopy. 
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4. Chalcones and Related Dienones as Inhibitors 
or Promoters of Tubulin Polymerization (Paper II) 
 
 
 
4.1  INTRODUCTION 
 
4.1.1  Tubulin and microtubules 
Microtubules are filamentous components of the cytoskeleton, constructed by tube-
shaped protein polymers, formed by - and -tubulin heterodimers (Figure 18).111-114 In 
eukaryotic cells, microtubules form a dynamic network that is essential in cellular 
processes such as mitosis, maintenance of cell shape, cytoplasmic organelle movement 
and cell replication.  
 
 
Figure 18. The structure and formation of microtubules. Tubulin exists in two forms within the cell, 
either as free protein heterodimers or as tube-shaped assemblies, referred to as microtubules.17, 111 These 
structures are constantly changing through polymerization and depolymerization, at the (+) and (-) ends, 
respectively, a dynamic feature that is essential in various cellular processes, such as mitosis. 
 
The structure of microtubules is consistently changing, i.e. they alternate between growing 
and shrinking through the addition and removal of tubulin molecules at the (+) and (-) 
ends, respectively. Thus, the function of microtubules is strongly associated with their 
stability and the dynamic character of the tubulin-microtubule equilibrium.17 Moreover, 
the microtubule assembly requires the association of two guanosine triphosphate (GTP) 
molecules for each tubulin heterodimer.115 One of them binds to an exchangeable site on 
the -tubulin subunit where it can be hydrolyzed to guanosine diphosphate (GDP), 
essential for microtubule elongation. In contrast, the other GTP nucleotide, which binds 
to -tubulin, is stable to hydrolysis and appears to have a structural role instead.113 The 
dynamic behavior of microtubules is essential for normal cell function and growth and is 
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affected by several factors including the intracellular GTP/GDP ratio, the ionic 
microenvironment and the presence of stabilizing microtubule-associated proteins.116 
 
The importance of tubulin and microtubules in chromosome segregation during cell 
division makes them attractive targets for anticancer drug design, i.e. in the development 
of antimitotic agents.111 Beneficially, the interference of tubulin/microtubule 
polymerization dynamics has two pivotal anticancer effects: i) inhibition of cancer cell 
proliferation through interruption of mitotic spindle formation, which leads to apoptosis, 
and ii) disruption of cell signaling pathways involved in regulating and maintaining the 
cytoskeleton of endothelial cells in tumor vasculature.117  
 
4.1.2  Tubulin as a target for antimitotic agents  
In general, antimitotic agents that interfere with tubulin dynamics act by targeting three 
different sites on the -tubulin subunit: the colchicine, the vinca alkaloid and the 
paclitaxel binding sites (Figure 19).17, 111 Agents that bind to the colchicine binding site 
(e.g. colchicine and podophyllotoxin, Figure 20) or to the vinca alkaloid domain (e.g. 
vincristine) induce depolymerization of tubulin and are therefore defined as inhibitors of 
tubulin assembly. In contrast, agents that target the paclitaxel binding site (e.g. taxanes 
such as paclitaxel and docetaxel, Figure 20) are known to stabilize the microtubule 
cytoskeleton against depolymerization, thus promoting tubulin assembly. Despite 
different mechanisms, both types of agents provide the same antimitotic effect, due to the 
conflict with tubulin/microtubule dynamics.  
 
 
 
Figure 19. Illustration of the tubulin ,-heterodimer with three major binding sites on the -tubulin 
subunit: the colchicine binding site, the paclitaxel binding site, and the vinca alkaloid domain.118 
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As depicted in Figure 20, antimitotic agents that target the tubulin heterodimer are 
obviously dominated by complicated natural occurring structures. Besides limited excess 
via extraction from naturally sources, such complex derivatives could be obtained using 
time-consuming total synthesis.119, 120 Consequently, the development of small, synthetic, 
and easily accessible compounds is of great interest in the field of oncology and in the 
development of tubulin modulators.111 
 
 
 
 
Figure 20. Chemical structures of known natural products that target tubulin and acts as antimitotic 
agents. Colchicine, vincristine and podophyllotoxin destabilize microtubule assembly, whereas paclitaxel 
and docetaxel act as promoters of tubulin polymerization.  
 
4.1.3  Chalcones as microtubule destabilizing agents 
Several chalcones have been reported to act as cytotoxic or microtubule destabilizing 
agents, preventing tubulin from polymerizing into microtubules.121-124 The majority of 
these are natural occurring compounds substituted with electron donating hydroxy 
and/or methoxy groups at various positions.16, 122, 125-127 However, the interest and 
development of synthetic chalcone derivatives as tubulin inhibitors has increased in recent 
years in order to establish more advanced structure-activity relationships and to generate 
novel compounds with diverse substituent patterns. For example, MDL 27048 (Figure 21) 
was one of the first synthetic chalcone-based tubulin inhibitors reported in the 
literature.123 Since its discovery in 1989, considerable efforts have been dedicated to 
identify new potential chalcone-based drug candidates within the field of oncology.128 
Despite this, MDL 27048 is still, to this date, one of the most potent synthetic inhibitors 
toward tubulin polymerization (IC50 = 12 nM).129  
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The pharmacological profile for chalcone derivatives has shown to be similar to the 
analogous combretastatins (Figure 21), a class of natural stilbenoids known for the activity 
as tumor vascular disrupting agents.17, 125, 130 Like colchicine and podophyllotoxin, 
combretastatins and chalcones bind to the colchicine binding site on -tubulin, thus 
inducing depolymerization of tubulin assembly.124, 131-133 It should be noted that, besides 
the interference of tubulin assembly, the cytotoxicity of chalcones can origin from other 
mechanisms involving inhibition of the tumor suppressor protein p53 (leading to 
dysregulation of the cell cycle in various tumor cell lines), blockage of nitric oxide 
production (important in macrophage-induced cytotoxicity) and inhibition of cytochrome 
P450 enzymes that are associated with the activation of procarcinogens.126, 134 
 
 
 
Figure 21. Chalcones are structurally related to combretastatins, natural occurring compounds that are 
known for their cytotoxic activity and inhibition of tubulin assembly.  Furthermore, MDL 27048 was one 
of the first reported synthetic chalcone-based tubulin inhibitors. 
 
4.2  RESULTS AND DISCUSSION 
The synthesis toward fluorescent and bioactive chromone-based compounds (Chapter 3, 
Paper I) generated a series of dihalogenated chalcone derivatives with various aromatic or 
conjugated B-rings. Due to numerous reports of chalcones and their anticancer activities, 
particularly as destabilizing agents of tubulin polymerization, we decided to investigate if 
our synthetic derivatives could act as tubulin inhibitors and/or cytotoxic agents.  
 
4.2.1  Synthesis of dihalogenated dienones 34-35  
As described earlier (section 3.2.1.1, Scheme 1), chalcones 3-5, 7, 10, 11 and dienone 8 
were prepared via a Claisen-Schmidt condensation of dihalogenated-2´-
hydroxyacetophenones 1-2 and various aromatic or conjugated aldehydes using aqueous 
NaOH (60%) in MeOH or KOH in EtOH.90-92 The series were extended with two 
dienone derivatives, 34 and 35. Compound 34 was obtained in low yields (26%), due to 
purification problems, using the latter reaction conditions described above (Scheme 5). 
The enol tautomer of 35 was synthesized in two steps from 3´-bromo-5´-chloro-2´-
hydroxyacetophenone 1 via esterification with benzoyl chloride, followed by a base-
promoted intramolecular Baker-Venkataraman rearrangement (Scheme 5).135, 136  
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Scheme 5. Synthesis of dienones 34 and 35. Reagents and conditions: (a) KOH, EtOH, 50 C  rt, 
overnight; (b) trans-cinnamoyl chloride, pyridine, rt, 48 h; (c) K2CO3, 2-butanone, reflux, 3.5 h. 
 
4.2.2  Cytotoxicity and antiproliferative studies 
The antiproliferative activity of compounds 3-5, 7, 8, 10, 11, 34 and 35 was evaluated 
using a fluorometric microculture cytotoxicity assay (FMCA), performed by co-workers at 
Uppsala University Hospital.137, 138 FMCA is a total cell kill assay, based on the ability of 
cells with intact cell membranes to convert non-fluorescent fluorescein diacetate (FDA) 
to fluorescent fluorescein. A panel of ten human cancer cell lines was used for the study, 
consisting of: RPMI 8226 (myeloma), CCRF-CEM (leukemia), U937-GTB (lymphoma) 
and NCI-H69 (small-cell lung cancer) along with the drug resistant sublines 8226/Dox40 
(doxorubicin resistant myeloma), 8226/LR5 (melphalan resistant myeloma), CEM/VM1 
(teniposide resistant leukemia), U937/Vcr (vincristine resistant lymphoma), H69AR 
(doxorubicin resistant small-cell lung cancer) and the primary resistant ACHN (renal 
adenocarcinoma) cell line. This panel has been designed to represent different histologies 
and different mechanisms of drug resistance.139 The cell suspensions (10,000-20,000 cells 
per mL) were exposed, at 37 °C, to varying concentrations of the test substances (0.016, 
0.08, 0.04, 2.00, 10.0 and 50.0 μM dissolved in DMSO with maximum 1% DMSO in cell 
suspensions) in 96-well microtiter plates for 72 h. Each compound concentration was 
tested in duplicate and the experiments were repeated twice. The cells were washed with 
phosphate-buffered saline (PBS) followed by the addition of FDA (dissolved in DMSO 
and diluted with physiological buffer to 10 μg/mL). The fluorescence, which is 
proportional to the number of living cells, was measured after 40 min incubation at 
485/520 nm, and the results were presented as survival index.  
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The results, depicted in Table 2, showed that all the assayed chalcones 3-5, 7, 10, 11, and 
dienones 8, 34, and 35, exhibit cytotoxic activities with noticeable differences in IC50 
values due to structural diversity. As expected, compounds 10 and 11 showed similar 
activity profiles in the majority of the cell lines, with the highest activity against NCI-H69 
(IC50 5.2 and 7.1 μM, respectively). However, the difference in cytotoxicity between 10 
and 11 in the renal adenocarcinoma cell line (ACHN) (IC50 164 and 69 μM, respectively) 
suggests that ACHN is sensitive to size modifications in the 5´-position of the chalcone 
structure. When comparing 4 and 7 (4-MeO-phenyl vs. 4-CF3-phenyl) the electron 
donating 4-methoxy group was unfavorable in three of the tested cell lines: CCRF-CEM, 
U973/Vcr and RPMI 8226. This result is more likely due to the difference in size between 
the trifluoromethyl and the methoxy group than the difference in electronic properties 
since the cytotoxic activity of 3 (no substituent on the phenyl group) is similar to that of 
7. Moreover, the 2-thienyl derivative 5 showed decreased activity in several of the cell 
lines in comparison with the slightly larger bioisosteric phenyl derivative 3, most 
noticeable in CCRF-CEM (IC50 152 vs. 37.6 μM). Elongation of the carbon chain 
between the aromatic moieties in 3 to obtain 8 also resulted in decreased activities. 
However, the introduction of a diketone/enol fragment as in 35 improved the activity 
with IC50 values corresponding to those of 3. Moreover, introducing an additional 
aromatic moiety, such as in 34, gave low activity in several of the tested cell lines, e.g. 
CCRF-CEM (IC50 280 μM), while a higher activity was observed toward the small-cell 
lung cancer cell line (NCI-H69) (IC50 11.1 μM). Interestingly, 34 showed the highest 
activity among the tested compounds toward the ACHN cell line (IC50 17.0 μM), known 
for its aggressive growth and high resistance profile.140  
 
Table 2.  Cytotoxicity data of chalcones 3-5, 7, 10-11 and dienones 8, 34-35 against ten human cancer cell 
lines.  
 
Cmpd Cytotoxicity, IC50 (μM) 
 
 
 CCRF-
CEM 
CEM/ 
VM1 
ACHN U937 
GTB 
U973/ 
Vcr 
RPMI  
8226 
8226/ 
Dox40 
8226/ 
LR5 
NCI- 
H69 
H69A
R 
3 37.6 22.3 48.9 20.0 24.2 18.7 12.4 13.2 10.3 26.4 
4 111a 45.8 49.4 45.0 77a 80a 16.9 46.0 16.4 42.6 
5 152a 48.9 44.2 42.5 32.6 79a 26.5 23.3 20.0 56.1 
7 15.4 31.1 49.4 14.9 24.4 20.8 22.5 22.3 11.5 33.2 
8 129a 48.6 93a 36.6 31.7 48.8 14.2 23.4 19.9 n.d.b 
10 14.8 14.5 164a 9.3 8.8 29.4 9.7 9.4 5.2 24.5 
11 20.1 13.1 69a 8.2 9.6 26.1 7.7 9.9 7.1 38.8 
34 280a 89a 17.0 49.0 54a 119a 42.3 70a 11.1 48.5 
35 34.1 24.1 37.8 18.1 23.9 27.9 19.1 33.5 9.4 25.5 
a Extrapolated values (highest tested concentration of 50 µM). b Not determined (no cytotoxic effect was 
observed). 
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4.2.3  The effect on tubulin polymerization 
Effects on tubulin polymerization were monitored using a commercial Tubulin 
Polymerization Assay Kit (porcine tubulin and fluorescence based), performed by co-
workers at Uppsala University Hospital.141, 142 The chalcones 3-5, 7, 10, 11, and dienones, 
8, 34, and 35 (dissolved in DMSO) were evaluated at 5 and 25 µM, and the experiments 
were performed twice (mean values are presented). Docetaxel and vincristine (3 µM, 
diluted in PBS) were used as positive stabilizing and destabilizing controls, respectively.  
 
 
 
Figure 22. Tubulin polymerization activity in the presence of compounds 3-5, 7, 8, 10, 11, 34 and 35 (at 5 
or 25 μM, mean values presented) with vincristine and docetaxel (at 3 μM) as reference compounds. 
Stacks below the horizontal (grey) line indicate tubulin inhibition, stacks above indicate tubulin 
stabilization and stacks close to the horizontal line are considered to represent inactive compounds. The y-
axis demonstrates tubulin polymerization activity measured at 15 min (arbitrary units) in the growth phase 
of the tubulin polymerization curve. 
 
The tubulin polymerization activity of compounds 3-5, 7, 8, 10, 11, 34, and 35 is depicted 
in Figures 22 and 23. Compounds 4, 7, and 35 showed no significant activity toward 
tubulin assembly, which suggests a different mechanism for their observed cytotoxic 
activity. However, chalcones 3, 5, 10, and 11 along with dienone 8 were identified as 
tubulin-destabilizing agents. In contrast, chalcone 34 displayed microtubule-stabilizing 
activity comparable to the well-established antimitotic chemotherapeutic drug docetaxel, 
which is used in the treatment of several types of cancer.143 Interestingly, to the best of 
our knowledge, compound 34 is the first reported chalcone with microtubule-stabilizing 
activity.  
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Figure 23. Chemical structures of compounds 3-5, 7-8, 10-11, 34-35, and their activity toward tubulin 
dynamics.  
 
4.2.4  Molecular modeling and docking studies 
Molecular docking was performed in order to explore possible binding modes and 
orientations for the chalcones and the dienones that showed activity toward tubulin 
polymerization. The docking was accomplished using the Schrödinger Package with the 
MAESTRO interface.144 The structure of tubulin in complex with podophyllotoxin (PDB 
1SA1) and the structure of tubulin in complex with taxol (PDB 1JFF) were used for the 
study.114, 145, 146  
 
4.2.4.1  Docking into the colchicine binding site of β-tubulin  
Several chalcones have been reported to act as antimitotic agents, targeting the colchine 
binding site on -tubulin.17, 124 Therefore, it seemed reasonable to assume the same thing 
for our synthetic derivatives. Thus, the microtubule destabilizing compounds 3, 5, 8, 10 
and 11 along with the co-crystallized ligand podophyllotoxin, were docked into the 
colchicine binding site of tubulin using the podophyllotoxin-tubulin complex (PDB 
1SA1) as template.145, 146 Podophyllotoxin binds into a hydrophobic cavity on β-tubulin, 
which includes two hydrophobic pockets, I and II (Figure 24A); The benzodioxole 
fragment is located in the hydrophobic pocket I (hpI), surrounded by Met259, Ala316 and 
Lys352, whereas the trimethoxyphenyl moiety is located in the hydrophobic pocket II 
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(hpII), enclosed by Leu242, Ala250 and Leu255.147 The docking study suggested that 
chalcones 3 and 5 bind to the colchicine binding site by directing the phenyl or 2-thienyl 
moieties, respectively, into hpI (Figure 24B and C). Simultaneously, the 4-bromo-3-
chloro-2-hydroxyphenyl moieties could tentatively fit into the other hydrophobic pocket, 
hpII. Moreover, compounds 8, 10 and 11 are more elongated and are therefore not able to 
adopt a conformation that utilizes both hydrophobic areas. Instead, the styryl group in 8 
is directed out from the binding site and placed into the gap that leads to the hydrophobic 
areas (Figure 24D). However, the 4-bromo-3-chloro-2-hydroxyphenyl moiety is located in 
the same hydrophobic pocket (hpII) as the corresponding moiety in chalcone 3, but it 
seems to be buried deeper inside the pocket and thereby utilizes the area more efficiently. 
In contrast, compounds 10 and 11 bind in a flipped fashion; the 4-diethylaminophenyl 
group is placed into the hpII and the rest of the molecule is directed outwards from the 
active site (Figure 24E).  
 
 
Figure 24. Docking of the synthesized destabilizing agents and podophyllotoxin in the colchicine binding 
site of -tubulin: (A) podophyllotoxin, (B) compound 3, (C) compound 5, (D) compound 8, (E) 
compound 11. 
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The inactive compounds, 4, 7 and 35, were also docked into the colchicine binding site of 
tubulin in order to find an explanation why these do not possess the same destabilizing 
activity against tubulin assembly as 3, 5, 8 10 and 11. Interestingly, compounds 4 and 7 
(Figure 25 A and B) adopt the same flipped binding mode as 10 and 11 (Figure 24E). 
However, the methoxy or the trifluoromethyl group is not able to achieve contact with 
the hydrophobic pocket to the same extent as the diethylamino moiety in 10 and 11. 
Additionally, compound 35 (Figure 25C) was directed in a similar manner as 3 (Figure 
24B) but the 4-bromo-3-chloro-2-hydroxyphenyl moiety seems to adopt a slightly 
different angle and could therefore not reach as far into the pocket as the corresponding 
moiety in 3.  
 
 
 
Figure 25. Docking of the inactive compounds into the colchicine binding site of -tubulin: (A) 
compound 4, (B) compound 7 and (C) compound 35. 
 
4.2.4.2  Docking into the paclitaxel binding site of β-tubulin 
Drugs that target the paclitaxel-binding site on -tubulin are known to act as promotors 
of tubulin assembly. Accordingly, the microtubule stabilizing dienone 34 and the co-
crystallized ligand paclitaxel, were docked into the paclitaxel binding site of β-tubulin 
using the paclitaxel-tubulin crystal structure (PDB 1JFF).114, 145 The large and complex 
structure of paclitaxel binds to β-tubulin through multiple hydrophobic interactions 
(Figure 26A). The phenyl ring of the 2-benzoyl ester moiety is located in a hydrophobic 
cavity surrounded by Leu217, Leu219, Asp226, His229 and Leu230. Residues Val23, 
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Ala233, Ser236 and Phe272 generate a hydrophobic pocket occupied by the 3´-phenyl 
ring whereas the voluminous taxane ring is enclosed by the Pro274, Leu275, Thr276, 
Ser277, Arg278, Pro360, Arg369, Gly370 and Leu371 residues. Furthermore, the phenyl 
ring of the 3´-benzamido group is close to Val23 and the oxetane oxygen participates in 
hydrogen bonding with the backbone N-H of Thr276 (Figure 26C). Since dienone 34 is 
considerably smaller than paclitaxel, it is not able to fill the binding pocket to the same 
extent. However, the docking study showed that the three different aromatic moieties in 
34 are directed towards different hydrophobic regions in the paclitaxel binding site 
(Figure 26B). The indole fragment is buried inside the hydrophobic pocket that binds to 
the 3´-phenyl ring in paclitaxel. The N´-benzyl moiety enters the same pocket as the 2-
benzoyl phenyl group and the 4-bromo-3-chloro-2-hydroxyphenyl moiety is directed, via 
the alkene linker, down into a hydrophobic area, enclosed by Pro274, Thr276, Arg278, 
Gln282, Arg284, Leu286, and Leu371. Interestingly, the modeling study also suggested 
that 34 could interact via two hydrogen bonds with Thr276: one between the phenolic 
hydrogen and the alcohol oxygen (2.31 Å, -OH…O, 134) and one hydrogen bond 
between the carbonyl oxygen and N-H in the protein backbone (2.14 Å, C=O…H-N, 
171) (Figure 26D).  
 
 
 
Figure 26. Paclitaxel (A) and dienone 34 (B) docked into the paclitaxel binding site of tubulin. Panels C 
and D depict potential hydrogen bonding interactions (orange dashed lines) between paclitaxel or 34 and 
the Thr276 residue in the active site on the -tubulin subunit. 
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4.2.5  Study of the chemical reactivity with glutathione 
Chalcones are known Michael acceptors and the observed effects toward tubulin 
assembly may be due to the their reactivity as ,-unsaturated electrophiles.122 For 
instance, several reports of chalcones binding to -tubulin suggest the interaction with 
nucleophilic cysteine residues in the colchicine binding site, in particular Cys241.130, 148 
Accordingly, the reactivity towards thiols has been established in the presence of 
glutathione, a nucleophilic intracellular tripeptide with an essential role in xenobiotic 
metabolism and detoxification.126, 148 For that reason, a synthetic experiment was 
conducted in order to investigate the reactivity of the dihalogenated chalcone derivatives 
in the present study. A mixture of glutathione and compound 10 in THF was stirred at 37 
°C for 2 hours.149 However, subsequent TLC analysis of the reaction mixture showed that 
no glutathione conjugate was formed. Additionally, the result was supported by the 
docking study where none of the destabilizing compounds, 3, 5, 8, 10 and 11, appeared to 
interact with Cys241 due to the large distance between the electrophilic ,-unsaturated 
fragment and the nucleophilic thiol residue. In summary, the observed activity of the 
destabilizing agents toward tubulin dynamics is probably not a result of the reaction with 
cysteine residues in the colchicine binding site on -tubulin. 
 
4.3  CONCLUSIONS 
This study comprises a series of dihalogenated chalcones and related dienones with 
antiproliferative activities against ten individual cancer cell lines. Five compounds were 
established as inhibitors of tubulin assembly, and surprisingly, one dienone derivative was 
instead found to stabilize tubulin to the same extent as the well-known anticancer drug 
docetaxel. The remaining three compounds showed no significant effect on tubulin 
dynamics, which suggests a different mechanism for their observed cytotoxicity profiles. 
Disruption of tubulin assembly was favored by compounds containing unsubstituted 
aromatic B-rings (i.e., phenyl or 2-thienyl as in 3 or 5), an electron rich 4-
diethylaminophenyl group (as in 10 and 11) or an elongated styryl moiety in the 3-position 
of the chalcone structure (as in 8). Stabilization of tubulin polymerization was obtained in 
the presence of the significantly larger dienone structure 34 containing an additional 
aromatic moiety. Molecular docking studies suggested that the tubulin inhibitors bind into 
the colchicine binding site of -tubulin while the novel tubulin-stabilizing agent seems to 
interact with the paclitaxel binding site. To the best of our knowledge, compound 34 is 
the first reported chalcone with microtubule-stabilizing activity, which could be a starting 
point for the development of novel small molecule microtubule-stabilizing agents. 
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5. Development of Chromone-Based Kinase 
Inhibitors and Modulators (Papers III and IV) 
 
 
 
5.1  INTRODUCTION 
 
5.1.1  Protein kinases 
Protein kinases belong to a ubiquitous class of structurally related enzymes, expressed by 
518 genes encoded by the human genome, referred to as “the human kinome”. The 
protein kinase complement of the human kinome constitutes approximately 1.7% of all 
human genes, thus representing one of the largest families of genes in eukaryotes.150, 151  
 
Protein kinases catalyze the phosphorylation of specific proteins by transferring the -
phosphate from adenosine-5´-triphosphate (ATP) to the hydroxyl groups of serine, 
threonine or tyrosine residues (Figure 27). Hence, protein kinases are generally divided 
into two major classes: protein serine/threonine kinases (PSTKs) and protein tyrosine 
kinases (PTKs), and a minor class of dual specific kinases (DSKs), which utilize all three 
residues as substrates.152-155 Additionally, there are protein kinases that phosphorylate 
other amino acid residues, e.g. the histidine kinases. These enzymes have been found in 
eukaryotes but are primarily present in prokaryotes, plants and fungi.156, 157 
 
Phosphorylation of proteins is essential in signal transduction pathways and is involved in 
cellular processes such as DNA-replication, cell growth, metabolism, differentiation, 
motility, and apoptosis.150, 152, 158, 159 The reverse process can be achieved by phosphatases 
that dephosphorylate proteins. Consequently, the phosphorylation-dephosphorylation 
process acts as a molecular switch, turning the protein activity on and off to obtain 
different biological responses.160, 161 Approximately 30% of all cellular proteins are 
phosphorylated on at least one amino acid residue. This fact, together with the estimation 
of 10,000 different proteins in a conventional eukaryotic cell with an average length of 
~400 amino acids (17% which are serine, threonine or tyrosine residues), give ~70,000 
potential phosphorylation sites for any given kinase.153 
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Figure 27. The catalytic cycle of phosphorylation and dephosphorylation of proteins, which generally 
occurs on serine, threonine and tyrosine residues. 
 
Several common structural features of protein kinases have been identified from 
numerous X-ray studies.159, 162 In general, the characteristic protein kinase fold possesses a 
highly conserved catalytic domain, consisting of approximately 250 amino acids. These 
form a smaller N-terminal lobe of -sheets and a larger C-terminal lobe of -helices, 
which are connected via a linker that includes a short peptide fragment, referred to as the 
hinge region.152, 153, 159, 161, 163-166 ATP binds in a deep cleft located between the N- and the 
C-terminal lobes. The N-terminal lobe possesses a flexible glycine-rich loop that forms a 
lid on the top of ATP. This lid is crucial for catalysis and necessary for nucleotide 
positioning. Moreover, ATP-binding is characterized by two hydrogen bonds between the 
adenine moiety and the protein backbone of the hinge area (Figure 28). The ribose moiety 
is located in a polar pocket and interacts via hydrogen bonds to a carboxylate residue and 
to a backbone carbonyl oxygen within the kinase. Furthermore, the triphosphate group 
coordinates to a divalent metal ion, such as Mg2+, which also binds to an aspartate residue 
in the well conserved DFG-motif (Asp-Phe-Gly).161 
 
 
The DFG-sequence is located in the activation loop, which is an important site for 
substrate binding and protein phosphorylation. A large conformational change in the 
activation segment allows the kinase to transform between an active and inactive state. In 
the active state, the aspartate of the DFG-motif is directed into the ATP-binding site, 
referred to as “DFG-in”, and thus coordinates to the magnesium ion. At the same time, 
the phenylalanine residue of the DFG-motif is located in a hydrophobic pocket and is not 
accessible. In the inactive state, the aspartate residue points out from the ATP-binding 
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site, referred to “DFG-out”, and is not able to bind to the magnesium. Consequently, the 
phenylalanine is instead directed towards the ATP-binding site.161, 166 
 
 
 
Figure 28. Illustration of important regions and interactions within the ATP-binding site of kinases.164, 167 
 
5.1.2  MAP Kinases 
Protein kinases are divided into several subgroups, including the highly conserved 
mitogen activated protein kinases (MAPKs).168-170 These enzymes regulate numerous 
signal transduction pathways in cells and are implicated in pivotal cellular mechanisms, 
such as differentiation, proliferation, embryogenesis and apoptosis. Consequently, 
dysregulated activation of MAPK signaling has a major role in various human cancers and 
is also associated with inflammatory diseases and autoimmune disorders.168-170 The 
MAPKs are generally divided into four major groups; the extracellular regulated kinases 
(ERK1 and ERK2), the c-Jun amino-terminal kinases (JNK1, JNK2 and JNK3), the p38 
kinases (p38, p38, p38 and p38), and the ERK5/BMK1 kinases (Figure 29). These 
groups all respond to different types of extracellular stimuli. In general, the ERKs are 
activated by growth factors, mitogens, hormones and ligands for G-protein coupled 
receptors (GPCRs), whereas the JNKs and the p38 kinases respond to bacterial 
lipopolysacchrides (LPS), interleukine-1 (IL-1), tumor necrosis factor- (TNF-α), and 
environmental stresses, including UV light, temperature and osmotic shock. Moreover, 
both classes of stimuli can activate the ERK5/BMK1 pathway.171-173  
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Figure 29. Schematic illustration of mammalian MAPK pathways. MAP kinases are activated by 
phosphorylation cascades, usually comprised of two upstream protein kinases (MAPKKK and MAPKK). 
The activated MAP kinase is transported into the nucleus, where it phosphorylates and regulates its target 
proteins, which further initiate gene transcription and cell proliferation.168, 174, 175 
5.1.3  Protein kinases as drug targets 
Protein kinases are important regulators in signal transduction pathways and their catalytic 
activity is essential for the development and survival of eukaryotic organisms.150 
Dysregulation of kinase activity has been associated with a number of pathological 
pathways related to cancers, inflammation, autoimmune diseases and metabolic 
disorders.161, 165, 176 Thus, kinases constitute an important class of therapeutic targets in the 
pharmaceutical industry.161, 177 However, the design of kinase inhibitors is especially 
complex since the aim is to achieve selectivity for a small number of kinases within a 
family of more than 500 structurally related enzymes. Moreover, all kinases bind to the 
same cofactor, ATP, and they also exhibit proximate sequence homology with protein 
kinases of other organisms such as plants, fungi and yeasts.178 As a consequence, 
inhibitors that target the ATP-binding site often suffer from low selectivity profiles and 
cross-reactivity with other protein kinases. They also have to compete with high molar 
concentrations of intracellular ATP (~ 1-10 mM).152, 165, 179, 180 Despite these drawbacks, 
the majority of small molecule kinase inhibitors reported to date targets the ATP-binding 
site.152 However, apart from ATP-antagonism, several other inhibition strategies and 
mechanisms have been applied, including allosteric or covalent inhibition along with 
direct or indirect blocking of substrate binding.181  
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5.1.3.1  Type I and type II inhibitors, targeting the ATP-binding site 
The majority of small molecule protein kinase inhibitors target the ATP-binding site and 
act either as type I or type II inhibitors.161 Type I inhibitors are ATP-competitive, they 
generally bind to the active conformation of the protein kinase, i.e. to the DFG-in 
conformation. These inhibitors mimic the interactions of the adenine moiety of ATP, 
typically by the formation of 1-3 hydrogen bonds with backbone residues in the kinase 
hinge area. Potent and selective type I inhibitors can be developed through design of 
compounds that utilize specific regions in the ATP-binding site that are not occupied by 
ATP. Such a region is the back cavity (hydrophobic region I) guarded by the gatekeeper 
residue, which is located in the kinase hinge region (Figure 28).182 The nature and size of 
the gatekeeper regulates the shape and the conformation of the hydrophobic cavity. Thus, 
a bulky gatekeeper residue limits the size and generates a small inaccessible cavity, 
whereas a small gatekeeper allows the positioning of substituents in the large back 
cavity.164, 165, 183  
 
Type II inhibitors occupy the ATP binding pocket in the same manner as the type I 
inhibitors, but they also utilize an adjacent hydrophobic site present in the DFG-out 
conformation. Type II inhibitors preferentially bind to and stabilize the inactive 
conformation of the protein kinase, thus preventing activation.162, 164, 165 The development 
of type II inhibitors is preferable since it opens several opportunities to control selectivity 
and thereby to improve the use of such novel kinase inhibitors as drugs.  
 
5.1.3.2  Allosteric, type III inhibitors 
Type III inhibitors bind exclusively to a less conserved allosteric binding pocket on the 
kinase, which is spatially distinct from the ATP-binding site.184 Several kinases possess 
such a cavity, also referred to as the DFG-out pocket, adjacent (but not overlapping) to 
the ATP-binding site. Inhibitors that bind to this site can lock the kinase in the inactive, 
DFG-out conformation, thus preventing phosphorylation. Furthermore, allosteric 
inhibitors usually possess high selectivity and potency since they utilize binding sites and 
regulatory mechanisms that are unique to a particular kinase. 
 
5.1.4  The p38 MAP Kinase 
The human p38 MAP kinases comprise a family of serine/threonine kinases consisting of 
four isoforms: α, β, γ and δ.185-189 The α-isoform, p38α, is the best characterized and is 
known to be involved in the biosynthesis of pro-inflammatory cytokines such as 
interleukin-1 (IL-1) and tumor-necrosis factor  (TNF-) in lipopolysaccharide (LPS)-
stimulated human monocytes.186 Consequently, p38α is strongly associated with chronic 
inflammatory diseases such as rheumatoid arthritis, Crohn’s disease, and inflammatory 
bowel syndrome. The p38 MAPKs are activated by dual phosphorylation on Thr180 and 
Tyr182 residues, which are operated by upstream MAPKKs, in particular MKK3 and 
MKK6 (Figure 29). Indirectly, they are also activated by cellular stress such as osmotic 
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shock, UV-radiation, mechanic stress and lipopolysaccharide (LPS) exposure. 
Subsequently, p38 MAP kinases activate several substrates via phosphorylation including 
transcription factors (e.g. activating transcription factor 2, ATF2, and tumor suppressor 
protein p53) and proteins involved in various cellular processes such as cell cycle 
progression, stability and mRNA translation (e.g. heat shock protein 27, Hsp27).187 
 
Besides the strong association with inflammatory disorders, p38 kinases have been found 
to be overexpressed in human tumors and cancer cell lines.190, 191 For example, high 
concentrations of p38 kinases have been correlated with invasive and poor prognostic 
breast cancers.192 Notably, chronic inflammation is a potent cancer promoter and 
cytokines are important survival factors for cancer cells. Thus, inhibition of p38 kinases 
could be beneficial for the treatment of inflammatory-associated cancers.190 
 
5.1.4.1  p38 MAP kinase inhibitors 
The human p38α MAP kinase was originally identified as the molecular target of pyridyl 
imidazole derivatives, a class of compounds known to inhibit the biosynthesis of 
inflammatory cytokines.185, 186, 193 Pyridyl imidazoles, in particular those containing a 
vicinal 4-fluoro/pyridyl motif (e.g. SB-203580 and SKF-86002, Figure 30), are known to 
interact with the ATP-binding site of p38, thus preventing the activation of downstream 
kinases.194-197 A key interaction for these ATP-competitive compounds is a hydrogen 
bond between the pyridin-4-yl nitrogen and the backbone NH group of Met109 in the 
hinge region (Figure 31A).195, 197, 198 Furthermore, to obtain selectivity, the 4-fluorophenyl 
moiety utilizes a hydrophobic pocket (I), which is guarded by the gatekeeper residue 
(Thr106).195  
 
 
Figure 30. Structures of known p38α inhibitors. SB203580, SKF-86002, VX-745 and WO02059083 bind 
to the ATP-binding site. In contrast, BIRB-796 is an allosteric inhibitor that binds to a pocket adjacent to 
the ATP-binding site.  
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Another class of compounds that binds to the ATP-binding site of p38 is highly 
selective heteroaryl fused pyridones and derivatives thereof (e.g. VX-745 and 
WO02059083, Figure 30).199-202 These compounds are characterized by a non-
complementary carbonyl hydrogen bond-accepting group opposite to a backbone 
carbonyl in the hinge area (Figure 31B).198, 202 To avoid repulsion, the carbonyl group of 
the inhibitor induces a peptide flip in the hinge region, thus allowing formation of two 
hydrogen bonds between the NH nitrogens in the backbone of Met109 and Gly110. 
Additionally, the adjacent pyridone NH group forms a hydrogen bond to the backbone 
carbonyl oxygen of His107.198, 202 
 
 
 
Figure 31. Binding features and key interactions for three well-known p38 inhibitors. SB-203580 (A) 
and VX-745 (B) bind to the ATP-binding site of p38α. However, VX-745 binds in a different manner 
than SB-203580 since it induces a peptide flip between Met109 and Glu110 in the hinge region. In 
contrast, BIRB-796 binds in an allosteric pocket adjacent to the ATP-binding site.  
 
A third class of p38 inhibitors bind to an allosteric binding site, adjacent to the ATP-
binding pocket.164 Among those, the N,N´-diaryl urea derivative BIRB-796 (Figure 30 
and 31C) binds to the inactive conformation of p38 in a selectivity pocket formed by 
the displacement of the Phe residue in the DFG-out motif. 184, 203 Hence, BIRB-796 locks 
the protein in its inactive form and prevents ATP-binding due to steric overlap with the 
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Phe residue. Besides hydrophobic allosteric interaction, the urea group interacts via two 
hydrogen bonds: one between the NH hydrogen and the Glu71 side chain and one 
between the carbonyl oxygen and the backbone NH group of Asp168 in the DFG-
motif.198 Interestingly, BIRB-796 also extends into the adenine region of the ATP-binding 
site and forms a hydrogen bond between the morpholine oxygen and the backbone NH 
group of Met109 in the hinge region.164, 198 
 
5.1.5  The MEK1/2 MAP kinase kinases 
The Ras/Raf/MEK/ERK mitogen-activated protein (MAP) kinase pathway plays an 
important role in control and regulation of cell proliferation, survival and 
differentiation.168 Dysregulation of these kinases is strongly associated with oncogenesis 
in humans and are therefore attractive targets for the development of potential anticancer 
drugs.204 For example, high concentrations of activated MEK1/2 and ERK1/2 have been 
found in human tumors, particularly those present in colon, lung, pancreas, ovary and 
kidneys. MEK1/2 are dual specific MAP kinase kinases, which phosphorylate specific 
threonine and tyrosine residues on downstream ERK1 and ERK2, required for 
activation.205, 206 Furthermore, MEK1/2 are attractive targets in drug discovery since they 
possess restricted substrate specificity (ERK1/2), in comparison with other kinases.204 On 
the other hand, MEK1/2 are activated by several kinases, including Mos, A-raf, B-raf, 
Raf-1 and MEKK, which further is activated by growth factors, mitogens and GPCRs 
(Figure 29). Therefore, targeting MEK1/2, rather than upstream kinases, might offer a 
more efficient strategy toward the development of anticancer drugs than to target 
Ras/Raf/MEK/ERK signaling. 
 
5.1.5.1  MEK1/2 inhibitors 
MEK1 and MEK2 possess high sequence identity, with 86% homology in the catalytic 
domain.206 Thus, compounds that interact with MEK1/2 are non-selective between the 
two kinase isoforms. Several naturally occurring resorcyclic acid lactones, e.g. L-783277 
(Figure 32), have demonstrated ATP-competitive MEK1/2 inhibitory activity, targeting 
the ATP-binding site.204 A characteristic fragment for those compounds is the ,-
unsaturated cis-enone in the macrocycle that is associated with irreversible binding to 
nucleophilic cysteine residues in the active site. However, the most well-known and well-
characterized MEK1/MEK2 inhibitors are non-competitive and bind to an allosteric 
pocket adjacent to the MgATP site. Among those, CI-1040, PD0325901, PD98059, and 
U0126 (Figure 32) bind to the inactive, dephosphorylated form of MEK1/2. Thereby the 
activation via upstream kinases is prevented by a conformational change that locks the 
kinase in its inactive form.162, 171, 204, 206, 207 In fact, these compounds are not MEK1/2 
inhibitors. Instead, they are more correctly referred to as MEK1/2 modulators, since they 
inhibit the phosphorylation of MEK1/2, thus preventing its activation. Several CI-1040 
and U0126 analogs have been synthesized and studied with the aim to investigate and 
characterize important structural features for the activity toward MEK1/2.206, 208, 209 
However, only few investigations around the structure-activity relationships for the 
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chromone-based PD98059 have been performed considering the numerous reports of its 
in vitro and in vivo activity.210, 211 
 
 
 
Figure 32. Chemical structures of known MEK1/2 inhibitors. L-783277 (MEK1 IC50 4nM) binds to the 
ATP binding site of MEK1/2, whereas CI-1040 (MEK1/2 IC50 17nM), PD0325901 (MEK1 and MEK2 
IC50 1.1 and 0.79 nM, respectively), PD98059 (MEK1 IC50 10 M) and U0126 (MEK1 and MEK2 IC50 72 
and 58 nM, respectively) bind to an adjacent pocket and thereby act as allosteric modulators, preventing 
MEK1/2 activation.204 
5.2  DEVELOPMENT OF p38 MAP KINASE INHIBITORS (Paper III) 
The ambition of the present study was to use structure-based design in order to develop 
chromone-based p38 inhibitors. The aims were i) to evaluate if diarylated 4-
fluorophenyl/pyridyl chromones can adopt the same binding mode as the imidazole-
based SB203580 (Figure 31A), ii) to establish an appropriate substituent pattern on the 
chromone structure and iii) to study potential interactions with the ATP-binding site of 
p38 to obtain inhibitory activity. 
 
5.2.1  Docking studies of the ATP-binding site of p38 
The docking study was performed using the Schrödinger Package, MAESTRO interface.144 
The structure of p38 in complex with the inhibitor SB203580 (PDB 1A9U) was used for 
the study.145, 195 The study suggested that 3-(4-fluorophenyl)-2-(4-pyridyl)chromone 
derivatives (Figure 33) could adopt the same binding mode as the imidazole-based 
inhibitor SB203580 (Figure 31A). Accordingly, the pyridine-4-yl nitrogen could interact 
via a hydrogen bond to the backbone NH group of Met109 (2.14Å, N…H-N, 163°) at the 
same time as the 4-fluorophenyl moiety is directed into the hydrophobic pocket I. 
Furthermore, the chromone carbonyl oxygen could participate in a hydrogen bond to the 
side chain of Lys53 (1.95Å, C=O…H-N, 134°), in a similar fashion as one of the 
imidazole nitrogens in SB203580. The study also revealed that introduction of an amino 
functionality in the 2-position on the pyridyl moiety, such as an isopropylamine 
(compound 59, Figure 33B), could provide an additional hydrogen bond to the hinge 
area, i.e. between the NH and the backbone carbonyl oxygen of Met109 (2.14 Å, N-
H…O=C, 139°).212-216 A suitable R-group on this amine could possibly utilize an adjacent 
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hydrophobic pocket (II) in the ATP binding site. However, the choice of substituents on 
the amine did not seem to have any definite significance, as all the tested R-groups (alkyl, 
cyclic or aromatic) were oriented in the same fashion into the hydrophobic cavity. 
 
Based on the modeling study, we decided to synthesize a small series of 3-(4-
fluorophenyl)-2-(4-pyridyl)chromone derivatives that could be expected to bind efficiently 
to the ATP-binding site of p38α. 
 
 
Figure 33. (A) Suggested binding mode and hydrogen bond interactions of 2-(2-amino-4-pyridyl)-3-(4-
fluorophenyl)chromones in the ATP-binding site of p38. (B) Compound 59 docked into the ATP-
binding site of p38α (PDB 1A9U). 
 
5.2.2  Synthetic strategy A  
The initial synthetic strategy toward 2-(2-amino-4-pyridyl)-3-(4-fluorophenyl)chromones 
was based on the retrosynthetic analysis illustrated in Figure 34. Tentatively, the target 
compounds could be provided starting from commercially available 2´-
hydroxyacetophenone and 2-chloroisonicotinaldehyde via a base-promoted Claisen-
Schmidt condensation to generate the corresponding pyridylchalcones. These could 
further be cyclized to 2-(2-chloro-4-pyridyl)-3-hydroxychromones via the Algar–Flynn–
Oyamada reaction using alkaline hydrogen peroxide. Subsequent conversion of the 
hydroxyl group to the corresponding triflate could enable the introduction of a 4-
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fluorophenyl moiety via a palladium-mediated Suzuki cross-coupling reaction. Finally, the 
target compounds could be obtained using Buchwald-Hartwig amination reactions for the 
introduction of various amines in the 2-position on the pyridyl moiety. 
 
 
 
Figure 34. Retrosynthetic analysis for the synthesis of 2-(2-amino-4-pyridyl)-3-(4-fluorophenyl)chromone 
derivatives via the chalcone pathway.  
 
The synthesis of the pyridylchalcone 37 has earlier been reported in the literature, using a 
base-promoted aldol condensation protocol with isonicotinaldehyde and KOH in 
ethanol.217 However, after several attempts, we were not able to reproduce the reaction 
from the literature or isolate the desired products 37-38 (Scheme 6). The reaction was 
investigated using different conditions, such as stronger base (aqueous NaOH, 60%), 
varying reaction times and use of microwave heating, but unfortunately without any 
successful results. Thus, we had to change strategy and investigate alternative routes for 
the synthesis of the 2-(2-amino-4-pyridyl)-3-(4-fluorophenyl)chromone derivatives. 
 
 
 
Scheme 6. Chromone synthesis via the chalcone pathway. Reagents and conditions: (a) The appropriate 
isonicotinaldehyde, KOH, EtOH, 50 Crt, overnight. (b) benzaldehyde, KOH, EtOH, 50 C  rt, 
overnight (c) I2, EtOH, 150 C, microwave heating, 1h. 
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5.2.3  Synthetic strategy B 
Due to synthetic problems via the chalcone pathway a new synthetic strategy was 
investigated (Figure 35). Instead, the desired derivatives could be generated via the Baker–
Venkataraman rearrangement. Accordingly, the chromone ring system could be provided 
via esterification of 2´-hydroxyacetophenone with 2-chloroisonicotinoyl chloride followed 
by rearrangement to the corresponding diketone, which in turn could be cyclized to the 2-
(2-chloro-4-pyridyl)chromone under acidic conditions. Similarly to the first synthetic 
strategy (Figure 34), the 4-fluorophenyl moiety could then be introduced in the 3-position 
via halogenation and Suzuki cross-coupling. Finally, the target compounds could be 
provided using Buchwald-Hartwig amination reactions for the introduction of various 
amines in the 2-position on the pyridyl moiety. 
 
 
 
Figure 35. Retrosynthetic analysis for the synthesis of 2-(2-amino-4-pyridyl)-3-(4-fluorophenyl)chromone 
derivatives via the Baker-Venkataraman rearrangement. 
 
5.2.3.1  Synthesis of the chromone ring system 
Initially, one of the starting materials, 2-chloroisonicotinoyl chloride 42 was synthesized 
prior to the first esterification step (described in Figure 35). The acid chloride 42 was 
obtained in excellent yields (91%) from the corresponding carboxylic acid 41 using neat 
thionyl chloride at reflux (Scheme 7).218  
 
 
 
Scheme 7. Synthesis of 2-chloroisonicotinoyl chloride 42. Reagents and conditions: (a) SOCl2, reflux,  
28 h. 
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Subsequently, esters 43-44 were successfully obtained (90 and 89%, respectively) from 2´-
hydroxyacetophenone 36 and the appropriate acid chloride in pyridine at room 
temperature (Scheme 8).  
 
 
 
Scheme 8. Esterification of 2´-hydroxyacetophenone 36 to generate 43 and 44. Reagents and conditions: 
(a) isonicotinoyl chloride or 2-chloroisonicotinoyl chloride 42, pyridine, 0 C  rt, 2 h. 
 
The subsequent Baker-Venkataraman rearrangement, to obtain diketones, is usually 
performed in the presence of KOH, with pyridine as a solvent, using conventional 
heating at 50 C.90, 219 However, these reaction conditions gave diketone 45 in poor yields 
(19%) when using ester 43 (Table 3, Entry 1) and did not result in any product formation 
when using the chlorinated derivative 44 (Table 3, Entry 2). Other protocols in the 
literature reveal that the rearrangement can be accomplished using other bases such as 
DBU in pyridine or NaH in THF.220, 221 Thus, these protocols were tested in order to try 
to convert ester 44 to the corresponding diketone 46. However, treatment of ester 44 
with DBU in pyridine at 80 C gave no indication of product formation (Table 3, Entry 
3). In contrast, when using NaH in THF at 50 C, all ester 44 was consumed in 50 min 
(Table 3, Entry 4) and the reaction time could be reduced to 10 min when using 
microwave heating at 65 C (Table 3, Entry 5). However, when looking closer at the 
outcome of the reaction, we noticed that the major product was 2´-hydroxyacetophenone 
36 formed as a result of hydride mediated ester cleavage. The diketones 45 and 46 could 
finally be obtained in acceptable and reproducible yields (85 and 60%, respectively), when 
using the KOH/pyridine protocol with microwave heating at 100 C for 10 min (Table 3, 
Entries 6-7).  
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Table 3. Screening of reaction conditions for the Baker-Venkataraman rearrangement. 
 
 
 
Entry R Base Solvent 
Temp. (C) 
conditions 
Reaction 
time (min) 
Yield 
(%)a 
1 H KOH Pyridine 50  120 19 
2 Cl KOH Pyridine 50  120 n.r.b 
3 Cl DBU Pyridine 80  overnight n.r.b 
4 Cl NaH THF 50  50  n.d.c 
5 Cl NaH THF 65, mwd 10  n.d.c 
6 H KOH Pyridine 100, mwd 15  85 
7 Cl KOH Pyridine 100, mwd 10  60 
aIsolated yields. bn.r. = No reaction according to 1H NMR spectra of the crude reaction mixture.  
cn.d. = Not determined, 2´-hydroxyacetophenone was generated during the reaction due to ester  
cleavage. dmw = microwave heating. 
 
The 2-pyridylchromone derivatives 47-48 were provided in high yields (81 and 97%, 
respectively) via efficient acid-promoted cyclization in the microwave, using HCl in acetic 
acid at 60 °C for 30 min or concentrated sulfuric acid in ethanol at 100 °C for 15 min 
(Scheme 9).90, 99 Importantly, the latter reaction conditions could not be used for the 
cyclization of 45 since it only gave protonation of the pyridine nitrogen.  
 
 
 
Scheme 9. Synthesis of 47 and 48 via acid-promoted cyclization. Reagents and conditions: (a) HCl, acetic 
acid, 60 C, microwave heating, 30 min. (b) H2SO4, EtOH, 100 °C, microwave heating, 15 min.  
 
5.2.3.2  Halogenation in the 3-position 
Flavone 40 was synthesized and used as a model compound for the screening of viable 
reaction conditions for the introduction of bromine or iodine in the 3-position of the 
chromone structure. Accordingly, 2´-hydroxychalcone 39 was obtained in 67% yield, via 
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the Claisen-Schmidt reaction using 2´-hydroxyacetophenone 36, benzaldehyde, and KOH 
in ethanol (Scheme 6). Subsequently, microwave-assisted cyclization of 39 using 
molecular iodine in EtOH at 150 C for 60 min gave flavone 40 in excellent yield 
(99%).222, 223 
 
 Attempts to brominate 40 with molecular bromine in acetic acid at room temperature 
(Table 4, Entry 1) or with NBS in chloroform at 60 C (Table 4, Entry 2) were 
unsuccessful and did not give any product formation.224, 225 However, treatment with NBS 
in DMF at 60 C using microwave heating gave 3-bromoflavone 49 in low yields (22%) 
(Table 4, Entry 3). Furthermore, adjustment of the reaction time from 60 to 30 min 
increased the yield of 49 to 52% (Table 4, Entry 4). Nevertheless, using the same reaction 
conditions for the 2-pyridinechromone derivatives 47-48 were not as successful, giving 
the corresponding bromo derivatives 51 and 53 in 12 and 4%, respectively (Table 4, 
Entries 5-6). Instead, a couple of new halogenation protocols were tested, focusing on the 
introduction of iodine in the 3-position. Treatment of flavone 40 with NIS in DMF using 
microwave heating (Table 4, Entry 7) or molecular iodine and silver trifluoroacetate in 
dichloromethane at room temperature (Table 4, Entry 8) were unsuccessful.226, 227 On the 
other hand, using molecular iodine and CAN (cerium(IV) ammonium nitrate) in 
acetonitrile at 65 C gave 3-iodoflavone 50 in 29% yield (Table 4, Entry 9), using 
microwave heating at 130 C increased the yield to 67% (Table 4, Entry 10).228-231 
However, this procedure did not generate any product for the halogenation of the 2-
chloropyridine derivative 48 (Table 4, Entry 11). Consequently, several other procedures 
where investigated using 48 as starting material, such as bromination with molecular 
bromine in pyridine (Table 4, Entry 12) or NBS and AIBN in carbon tetrachloride (Table 
4, Entry 13).232-234 However these protocols were not successful and did not give the 
desired product. Furthermore, iodination attempts with molecular iodine and BEMP or 
BuLi in THF gave the same result, no product formation (Table 4, Entries 14-15). Finally, 
treatment of 48 with a commercial LDA solution (1.8 M) and molecular iodine gave 54 in 
42% yield (Table 4, Entry 16). If instead using in situ generated LDA, prepared from 
diisopropylamine and BuLi, the yield of 54 increased to 50% (Table 4, Entry 17) and gave 
52 in 88% yield (Table 4, Entry 18).235 Interestingly, the concentration of the reaction 
mixture proved to be important for the generation of 54 since dilution to 0.01M increased 
the yield to 80% (Table 4, Entry 19). However, we found that the reaction was not 
reproducible when using the 2-chloropyridine derivative 48. Instead, microwave assisted 
bromination of 48 using excess NBS (5 equiv) in DMF at 80 C for 60 min gave high and 
reproducible yields of 53 (94%) (Table 4, Entry 20). 
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Table 4. Screening for suitable reaction conditions for the introduction of halogens in the 3-position of 
the chromone structure.  
 
 
 
Entry R X Y Reagent 
Additive or 
base 
Solvent 
Temp. (C) 
conditions 
Reaction 
time 
(min) 
Yield 
(%)a 
1 H CH Br Br2  Acetic acid rt
b overnight n.rc 
2 H CH Br NBSd  CHCl3 60 300 n.r.
c 
3 H CH Br NBSd  DMF 60, mwe 60 22 
4 H CH Br NBSd  DMF 60, mwe 30 52 
5 H N Br NBSd  DMF 60, mwe 30 12 
6 Cl N Br NBSd  DMF 60, mwe 30 4 
7 H CH I NIS  DMF 150, mwe 90 n.r.c 
8 H CH I I2 CF3COOAg CH2Cl2 0 → rt
b overnight n.r.c 
9 H CH I I2 CAN Acetonitrile 65 overnight 29 
10 H CH I I2 CAN Acetonitrile 130, mw
e 60 67 
11 Cl N I I2 CAN Acetonitrile 130, mw
e 60 n.r.c 
12 Cl N Br Br2  Pyridine rt
b overnight n.r.c 
13 Cl N Br NBS AIBN CCl4 rt
b overnight n.r.c 
14 Cl N I I2 BEMP THF rt
b overnight n.r.c 
15 Cl N I I2 BuLi THF -78 → rt
b 60 n.r c 
16 Cl N I I2 LDA
f THF -78 → rtb 15 42 
17 Cl N I I2 LDA
g THFh -78 → rtb 15 50 
18 H N I I2 LDA
g THFh -78 → rt.b 15 88 
19 Cl N I I2 LDA
g THFi -78 → rtb 15 80j 
20 Cl N Br NBSk  DMF 80, mwe 60 94 
aIsolated yields. brt = room temperature. cn.r. = No reaction, according to 1H NMR spectra or TLC 
analysis of the crude reaction mixture. d1-2 equiv. emw = microwave heating. f1.8 M solution of LDA in 
THF/heptane/ethylbenzene. gIn situ generated LDA, from diisopropylamine and BuLi at -78 C in THF. 
hConcentration of mixture = 0.03 M. iConcentration of reaction mixture = 0.01 M. jThe reaction is not 
reproducible. k5 equiv. 
 
5.2.3.3  Arylation in the 3-position via a Suzuki cross-coupling reaction 
3-Bromoflavone 49 and phenylboronic acid were used as a model system in the search for 
viable reaction conditions for the introduction of aryl groups in the 3-position of the 
chromone structure. Notably, the introduction of various aryl groups on 3-
iodochromones via Suzuki coupling has previously been reported using Pd2(dpf)2Cl2 as a 
catalyst in dichloromethane.226 Instead, Pd(OAc)2(PPh3)2 was used as a catalyst, due to 
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previous successful results within the research group. However, the reaction with 49 and 
phenylboronic acid did not generate the desired product after refluxing overnight (Table 
5, Entry 1). The reaction was repeated with dichloroethane as a solvent, in order to 
increase the reaction temperature, but without any further improvement (Table 5, Entry 
2). Consequently, the attention was directed towards a Suzuki coupling protocol that has 
earlier been successfully applied to 5-iodotriazole derivatives in our research group.236-238 
However, following that procedure, using Pd(PPh3)4 and K2CO3 in DMF/H2O (9:1) at 
100 C overnight, did not either generate the desired product (Table 5, Entry 3). Several 
other Suzuki protocols were explored, e.g. treatment with Pd/C (10%) and Na2CO3 in 
DME/ H2O (1:1) (Table 5, Entry 4), but none of them resulted in product formation.239 
Finally, product 55 was obtained in 65% yield via an oxygen-promoted ligand-free Suzuki 
procedure using palladium(II) acetate and K2CO3 in PEG-400 at 45 C for 24 hours 
(Table 5, Entry 5).240-242 The yield of 55 was increased to 84% using microwave heating at 
60 C for 30 min (Table 5, Entry 6). This procedure has been reported to involve the 
generation of highly active palladium nanoparticles, which are stabilized by oxygen.240 
Additionally, the solvent, polyethylene glycol (PEG-400), acts as a reductant, reducing 
Pd(II) to Pd(0). Furthermore, the latter Suzuki protocol was also used for the 
introduction of the 4-fluorophenyl group in the 3-position of the flavone 49, giving 56 in 
17% (Table 5, Entry 7). Next, the 4-fluorophenyl moiety was introduced in the 3-position 
of the 3-iodo-2-pyridylchromone derivatives 52 and 54. Accordingly, the Suzuki reactions 
were performed in the presence of 4-fluoroboronic acid, palladium(II)acetate and K2CO3 
in PEG-400 using microwave heating at 60 C for 90 min, affording 57 and 58 in 47 and 
62% yield, respectively (Table 5, Entries 8-9). In addition, the same protocol was also 
used for the introduction of the 4-fluorophenyl group in the 3-position of the 3-bromo-2-
pyridylchromone derivative 53, which gave 58 in 59% yield (Table 5, Entry 10).  
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Table 5. Screening for viable Suzuki cross-coupling conditions for the introduction of aryl groups in the 
3-position of the chromone ring system. 
 
 
 
Entry R X Y Z Catalyst Base Solvent 
Temp. 
(C) 
conditions 
Reaction 
time 
(min) 
Yield 
(%)a 
1 H CH Br H Pd(OAc)2(PPh3)2
  K2CO3 CH2Cl2 reflux overnight n.r.
b 
2 H CH Br H Pd(OAc)2(PPh3)2 K2CO3 
Dichloro- 
ethane 
reflux 24 h n.r.b 
3 H CH Br H Pd(PPh3)4
  K2CO3 
DMF/H2O 
(9:1) 
100 overnight n.r.b 
4 H CH Br H Pd/C (10%)  Na2CO3 
DME/ 
H2O (1:1) 
80 overnight n.r.b 
5 H CH Br H Pd(OAc)2
c K2CO3 PEG-400 45 24 h 65 
6 H CH Br H Pd(OAc)2
c K2CO3 PEG-400 60, mw
d 30  84 
7 H CH Br F Pd(OAc)2
c  K2CO3 PEG-400 60, mw
d 30  17 
8 H N I F Pd(OAc)2
c K2CO3 PEG-400 60, mw
d 90  47 
9 Cl N I F Pd(OAc)2
c  K2CO3 PEG-400 60, mw
d 90  62 
10 Cl N Br F Pd(OAc)2
e  K2CO3 PEG-400 60, mw
d 90  59 
aIsolated yields. bn.r. = No reaction, according to 1H NMR or TLC analysis of the crude reaction mixture. 
c0.1 equiv. dmw = microwave heating. e0.3 equiv. 
 
5.2.3.4  Introduction of amines via the Buchwald-Hartwig reaction  
The final compounds 59-65 were obtained from the pyridyl chloride 58 using microwave 
assisted Buchwald-Hartwig amination in the presence of various primary amines (Scheme 
10). Compound 59 was generated in 49% yield using isopropylamine, palladium(II) 
acetate, sodium tert-butoxide, and 2-(dicyclohexylphosphino)biphenyl in toluene at 130 °C 
for 90 min.243 However, for the introduction of other amines, a more efficient bidentate 
ligand was required and compounds 60-65 could be obtained in 49-77% yield using 
microwave heating in the presence of the appropriate amine, palladium(II)acetate, sodium 
tert-butoxide, and 1,3-bis(diphenylphosphino)propane in toluene at 130 °C for 90 min.244 
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Scheme 10. Synthesis of the final compounds 59-65 via Buchwald-Hartwig amination. Reagents and 
conditions: a) R-NH2, NaOt-Bu, Pd(OAc)2, 2-(dicyclohexylphosphino)biphenyl or 1,3-
bis(diphenylphosphino)propane, toluene, 130 C, 90 min, microwave heating. 
 
5.2.4  Biological evaluation of compounds 57-65 toward p38 
Compounds 57-65 were evaluated using a commercial radiometric p38 assay performed 
by Millipore KinaseProfilerTM service.245 It should be noted that a fluorescent-based assay 
could not be used since the compounds themselves exhibit fluorescent properties. As 
depicted in Table 6, all of the tested compounds 57-65 showed inhibitory activity toward 
the p38 kinase and the IC50 values were compared to the known p38 inhibitor 
SB203580 (IC50 84 nM). Satisfyingly, the highest inhibitory activity in the series was 
observed for the isopropylamino derivative 59 (IC50 17 nM). The analogs 60-61 and 63-65 
showed similar inhibitory potency (IC50 21-45 nM) indicating that p38 is relatively 
flexible and can accept different amino groups in the 2-position of the pyridyl moiety. 
However, the 3-(dimethylamino)propylamino derivative 62 displayed a decreased activity 
(IC50 761 nM), which could imply that a polar group or a distal positive charge (at 
physiological pH) is disadvantageous for the activity. Furthermore, differences in the 
activity between 57 and 58 (IC50 813 and 1380, respectively) apparently originate from the 
electron withdrawing properties of the chlorine atom in 58. Hence, the adjacent pyridine 
nitrogen becomes a less effective hydrogen bond acceptor resulting in a weaker 
interaction with the hinge area in the ATP-binding site of p38.  
 
5.2.5  Kinase selectivity screening of 59 and 63 
Two of the inhibitors, 59 and 63, were evaluated in a selectivity screen with a panel of 54 
kinases chosen to represent the human kinome and eight kinases closely related to p38 
(Paper III, Supporting information).245 The study revealed an excellent selectivity profile 
for the p38 and p38 isoforms, with the exception for an observed activity against the 
JNK2 and JNK3 kinases (58 and 21% remaining activity, respectively for compound 59). 
However, this kind of cross-reactivity, in particular with JNK3, has been reported earlier 
for chromone-based p38 inhibitors.246 In addition, the observed selectivity for p38 and 
p38 over the closely related p38 and p38 isoforms was expected due to the nature of 
different gatekeeper residues in the selectivity pocket in the ATP-binding site (threonine 
in p38 and p38, methionine in p38 and p38).164, 198 
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Table 6. Biological activity of SB203580 and 57-65 against the p38 MAP kinase.  
 
Compound Structure 
IC50 
(nM) 
p38α 
Compound Structure 
IC50 
(nM) 
p38α 
SB203580 
 
84 61 
 
 
39 
57 
 
 
 
813 62 
 
 
761 
58 
 
1380 63 
 
 
 
34 
59 
 
 
17 64 
 
 
 
45 
60 
 
 
21 65 
 
 
35 
 
59 
 
Based on the results from the selectivity screen, the inhibitory activity for compounds 59 
and 63 were also established toward p38 (IC50 36 and 154 nM, respectively) and JNK3 
(IC50 505 and 394, respectively).245 Interestingly, the difference in activity between 59 and 
63 against p38 suggests that the -isoform, unlike p38, is sensitive to size 
modifications (isopropylamino vs. cyclohexylamino) in the 2-position of the pyridyl 
moiety. The lower activity toward JNK3 can also be explained, as stated earlier, by the 
nature of the gatekeeper residue. As for p38 and p38, the JNK family possesses a 
methionine gatekeeper residue that blocks the entrance to the selectivity pocket 
(hydrophobic pocket I, Figure 31A).198 
 
5.2.6  Studies on the effect of p38 kinase signaling in human breast cancer cells 
The p38 kinases are highly expressed in severe breast cancers and studies have shown that 
inhibition of the p38 kinases suppresses the proliferation of human breast cancer cells.192 
Thus, the efficiency of compound 63 was evaluate in a cell-based assay with human 
derived MCF-7 breast cancer cells.247 The study showed that anisomycin-induced 
activation of p38 signaling, as shown for the p38 phosphorylation targets: activating 
transcription factor 2 (ATF2) and heat shock protein 27 (HSP27), was inhibited by doses 
as low as 0.5 M, and maximal inhibition was observed at 10 M (Figure 36). 
Interestingly, 63 also inhibits phosphorylation of p38 itself, which occurs without 
affecting the total levels of the enzyme, ruling out an effect on protein stability of the 
inhibitor as the mechanism. 
 
Figure 36. Compound 63 inhibits p38 kinase activation and signaling in human MCF-7 breast cancer 
cells. MCF-7 cells were preincubated with the indicated doses of 63 for 30 min and subsequently exposed 
to 10g/mL anisomycin for another 30 min. Total cell lysates were resolved by SDS-PAGE and 
membranes were probed with antibodies directed against phosphorylated ATF2, p38, and HSP27. 
Tubulin was used as a loading control. 
 
An additional experiment showed that phosphorylation of MKK3 and MKK6, the 
upstream activators of p38, was unaffected by 63 (Figure 37). Thus, the loss of p38 
phosphorylation, induced by 63, does not appear to result from the inhibition of 
upstream signaling. Furthermore, 59 and 63 did not significantly affect the proliferation of 
MCF-7 or MDA-MB436 cells, neither of the compounds enhanced sensitivity to 
anisomycin or doxorubicin in MCF-7 cells (Paper III, Supporting information). However, 
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both 59 and 63 appeared to suppress the sensitivity of MDA-MB436 cells, harboring a 
p53-mutation, to doxorubicin. This observation was unexpected since p38 kinase activity 
has previously been shown to suppress sensitivity to genotoxic agents in p53 negative 
cells.248  
 
 
Figure 37. Phosphorylation of the MAP kinase kinase MKK3/6 is unaffected by 63. MCF-7 breast 
cancer cells were preincubated with the indicated concentrations of 63 for 30 min and subsequently 
exposed to 10g/mL anisomycin for another 30 min. Total cell lysates were resolved by SDS-PAGE and 
membranes were probed with antibodies directed against phospho-MKK3/6 (Ser189/207). Antibodies 
directed against poly (ADP-ribose) polymerase (PARP) were used as a loading control. 
 
5.3  DEVELOPMENT OF ALLOSTERIC MEK1 MODULATORS (Paper IV) 
The objective of this study was to design and synthesize chromone-based allosteric 
MEK1 modulators. Thus, we wanted to use PD98059 (Figure 32) as a starting point since 
it is a well-known allosteric chromone-based MEK1/2 modulator (MEK1 IC50 10 
M).204, 249-251 Several studies of PD98059 reveal a high selectivity profile against the 
MEK1/2 kinases, in vitro and in vivo, along with cytotoxic effects toward several 
different cancer cell lines including leukemic and breast cancer cells.252, 253 Furthermore, 
docetaxel-induced apoptosis of androgen-independent prostate cancer cells have shown 
to be greatly enhanced by its combination with PD98059.254 Despite numerous reports of 
PD98059 as a selective MEK1/2 inhibitor and its use as a chemotherapeutic agent against 
different types of cancers, there are few reports on PD98059 analogues and the structure-
activity relationship toward MEK1/2.210, 211 Therefore, we wanted to use molecular 
docking in order to identify potential structural modifications of the PD98059 structure 
that would result in optimized and highly potent allosteric MEK1 modulators.  
 
5.3.1  Docking studies into the allosteric pocket of MEK1 
The docking study was performed using the Schrödinger Package, MAESTRO interface.144 
The structure of MEK1 bound to ATPMg in complex with the allosteric modulator 
PD0325901 (Figure 32) (PDB 1S9J) was used for the study.145, 255 The MEK1 structure, 
PD0325901, PD98059 and various chromone derivatives were prepared and energy 
minimized using ligand preparation. Molecular docking was performed using GLIDE with 
extra precision (XP) settings and standard parameters for ligand docking.  
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Figure 38 shows selected examples of molecules docked into the allosteric site of MEK1. 
For example, PD0325901 binds into the hydrophobic allosteric pocket of MEK1 (Figure 
38A) via one hydrogen bond between the hydroxamic acid oxygen and the side chain of 
Lys97 (2.14 Å, O…H-N, 144°). Additionally, the dihydroxypropoxy moiety utilizes a 
hydrophobic cavity that links the allosteric pocket and the ATP-binding site. Thus, the 
diol fragment forms two hydrogen bonds with the triphosphate group in ATP, one 
between the primary alcohol and the α-phosphate group (1.84 Å, O-H…O-P, 112°) and 
one between the secondary alcohol and the γ-phosphate (1.97 Å, O-H…O-P, 103°). 
Furthermore, the study suggested that PD98059 (Figure 38B) forms two hydrogen bonds 
with the protein backbone; one between the chromone carbonyl oxygen and NH of 
Ser212 in the activation loop (2.16 Å, C=O…H-N, 165°) and one between the aniline 
NH2 and the carbonyl oxygen of Phe209 (1.99 Å, N-H…O=C, 172°). Additionally, 
PD98059 does not utilize the hydrophobic tunnel that links to the ATP-binding site 
(Figure 38B), as shown for PD0325901 (Figure 38A). Nevertheless, the docking study 
suggested that substituents in the 8-position on the chromone structure could preferably 
extend toward the ATP-binding site. For example, introduction of an aminopropyl group 
in the 8-position (e.g. via Pd-mediated cross coupling of a halogenated chromone 
derivative with an allylamine) could tentatively reach down to the ATP-binding site. 
According to the docking model the terminal positively charged amino functionality could 
bind to the γ-phosphate group in ATP (2.07 Å, N-H…O-P, 142°) (Figure 38C). The study 
also indicated that the amino group could interact via an additional hydrogen bond to the 
side chain of Asp190 (1.79, N-H…O=C, 162°). Based on these observations, we wanted 
to explore the use of 3´-bromo-5´-chloro-2´-hydroxyacetophenone as a starting material 
for the synthesis of 8-substituted PD98059 analogues, due to its commercial availability 
and low price in comparison with 3´-halogenated 2´-hydroxyacetophenones. However, 
this must require that a chlorine atom in the 6-position of the chromone structure does 
not affect the activity or the binding negatively. The chlorine atom in the 6-position, as in 
81 or 85, did not seem to affect the docking or binding mode into the allosteric pocket 
(Figure 38C). In fact, the chlorine atom could possibly act as a handle (e.g. Pd-mediated 
coupling reactions) for further modifications since the allosteric pocket extends in the 
corresponding direction. We also observed that the methoxy group in the 3´-position of 
PD98059 could be replaced with an ethoxy group, which could utilize the area more 
efficiently (80, Figure 38D). Based on the modeling study we decided to synthesize a few 
PD98059 analogs and evaluate their biological activity toward MEK1.  
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Figure 38. Docking of PD0325901 (A), PD98059 (B) 85 (C) and 80 (D) into the allosteric pocket of 
MEK1. The adjacent ATP-binding site is located below the allosteric pocket in the figure, thus a part of 
the ATP molecule can be depicted at the bottom of the panels. 
5.3.2  Synthesis of PD98059 analogs 
The two-step synthesis of PD98059, 2´-amino-3´-methoxyflavone (Figure 32) has 
previously been reported starting from 2-pivaloylamino-3-methoxyacetophenone and 
methyl 2-[(tert-butyl-dimethylsilyl)oxy]-benzoate (Figure 39).256 Interestingly, this 
procedure is, to our knowledge, the only available synthetic protocol for PD98059. 
However, we wanted to use the same synthetic route as we used for the synthesis of the 
chromone-based p38 inhibitors, i.e. via the Baker-Venkataraman rearrangement, starting 
from 2´-hydroxyacetophenones (Section 5.2.3). 
 
 
 
Figure 39. Synthetic protocol of PD98059 from the literature via base-promoted condensation 
(LiHMDS, THF, -78 °C → rt, 43 h) of 2-pivaloylamino-3-methoxyaetophenone and methyl 2-[(tert-butyl-
dimethylsilyl)oxy]benzoate followed by acid-catalyzed cyclization (H2SO4, acetic acid, 100 °C, 3 h).256 
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5.3.2.1  Synthesis of flavones 75-77 
Esters 69-71 were successfully obtained in 70-92% yield from 2´-hydroxyacetophenones 
(1, 36 or 66) and the appropriate acid chlorides, which were prepared in situ from the 
corresponding carboxylic acids, 67-68, using oxalyl chloride or thionyl chloride as 
chlorinating agents (Scheme 11).218, 257 The 2-nitrobenzoic acids 67-68 were used with the 
aim to later convert the nitro group to the corresponding amine under reductive reaction 
conditions.  
 
 
 
Scheme 11. Synthesis of flavones 75-77. Reagents and conditions: (a) (i) oxalyl chloride, DMF, 
dichloromethane, rt, 2 h or SOCl2, toluene, reflux, 20 h; (ii) pyridine, 0 C  rt, 1-2.5 h. (b) KOH, 
pyridine, 50 C, 30 min, conventional heating or 100 C, 30 min, microwave heating. (c) H2SO4, acetic 
acid, reflux, 45 min or H2SO4, EtOH, 100 C, 30 min, microwave heating. 
 
Notably, one of the carboxylic acids 67 was synthesized, in two steps from 3-hydroxy-2-
nitrobenzoic acid 78 (Scheme 12). Accordingly, 78 was O-alkylated to give 79 in 93% yield 
using ethyl iodide and K2CO3 in DMF.258 Thereafter, the simultaneously generated ethyl 
ester was hydrolyzed using 0.1 M NaOH in order to provide 67 in 88% yield. Base-
promoted rearrangement of 69-71 to obtain diketones 72-74 was carried out in pyridine 
using conventional heating at 50 C or microwave heating at 100 C for 30 min (Scheme 
11).90, 99 Subsequently, acid-promoted cyclization gave the flavones 75-77 in high yields 
(68-99%). 
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Scheme 12. Synthesis of 3-ethoxy-2-nitrobenzoic acid 67. Reagents and conditions: (a) ethyl iodide, 
K2CO3, DMF, 60 °C, 2 h. (b) 0.1 M NaOH, reflux, 1 h. 
 
The nitro functionality in 75-76 was successfully converted to the corresponding amine 
under acidic conditions using tin as a reducing agent in ethanol to afford 80-81 in 80% 
and 68% yield, respectively (Scheme 13).36 
 
 
 
Scheme 13. Reduction of the nitro functionality in 75-76. Reagents and conditions: (a) Sn powder, conc. 
HCl, EtOH, reflux, 1 h. 
 
5.3.2.2  Synthesis of 85 via the Heck reaction 
Regioselective introduction of N-Boc-protected allylamine in the 8-position of the 
dihalogenated flavone 77 was achieved using the Heck reaction under inert conditions 
(Scheme 14). Compound 77 was treated with N-Boc-allylamine, PdCl2[P(o-Tol)3]2 and 
triethylamine in acetonitrile at 75 °C overnight to give the pure product 82 in low yield 
(11%).259 In addition, fractions of a mixture of the target compound 82 and the enamine 
product 83, as a mixture of E/Z isomers (1:1), was obtained in 34% yield.  
 
 
 
Scheme 14. Introduction of N-Boc-protected allylamine in the 8-position via the Heck reaction. Reagents 
and conditions: (a) N-Boc-allylamine, PdCl2[P(o-Tol)3]2, Et3N, acetonitrile, 75 °C, overnight. 
 
Reduction of the nitro group to the corresponding amine and reduction of the olefin in a 
mixture of 82 and 83 was performed simultaneously by catalytic hydrogenation over 
Pd/C (10%) using an H-Cube® Continuous-flow Hydrogenation Reactor (Scheme 15). 
The product 84 was obtained in low yields (33%), which could be explained by the 
observation of the formation of at least two byproducts; dehalogenated product together 
with a product where the olefin had been reduced but not the nitro group. Subsequent 
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acid-promoted deprotection of the Boc-group in 84 using TFA in dichloromethane gave 
the target compound 85 in 78%. 
 
 
 
Scheme 15. Synthesis of the target compound 85. Reagents and conditions: (a) H2 (H-cube®), Pd/C 
(10%), THF, 20 °C, 30 bar. (b) trifluoroacetic acid, dichloromethane, room temperature, overnight. 
 
5.3.3  Biological evaluation of compounds 80, 81 and 85 as MEK1 modulators 
The enzymatic activity of MEK1 in the presence of 80, 81, or 85, was evaluated by 
measuring its ability to increase myelin basic protein (MBP) kinase activity of ERK2 in 
vitro. The study was performed by co-workers at Université de Montréal, Canada. The 
results show that the synthesized compounds 80, 81 and 85 inhibit Raf-1 induced 
activation of MEK1 with similar activities (IC50 1.9-6.4 M) as for PD98059 (IC50 10 
M),204 with the highest activity for 80 (IC50 1.9 M) (Table 7). Interestingly, the 
replacement of the methoxy group in the 3´-position (PD98059) on the chromone 
structure for an ethoxy group, as in 80, gave a five-fold increase of the activity (IC50 10.0 
vs. 1.9 M). Furthermore, introduction of a propylamine in the 8-position, as in 85, did 
not increase the activity as much as anticipated. However, going back to the modeling 
study, this could be explained by the positioning of the carbonyl and aniline amine of 85 
in the allosteric pocket. The structure is placed somewhat further down towards the ATP-
binding site, which prevents the interaction between the chromone carbonyl and Ser212. 
According to this observation, it would be interesting to extend the propyl chain in the 8-
position by one carbon, to a butylamine. This strategy could possibly give interactions 
between the amino group to ATP and Asp190 at the same time as the distance between 
the chromone carbonyl and Ser212 would be optimized for hydrogen bonding. Although 
81 showed the lowest activity of the three synthesized compounds (IC50 6.4 M), it seems 
that the chloride in the 6-position does not affect the activity (PD98059 vs. 81, IC50 10.0 
and 6.4, respectively). However, in order to optimize the potency for a second generation 
of chromone-based MEK1 modulators it would be preferable without a substituent in the 
6-position. Nevertheless, it does not necessarily exclude the use of 3´-bromo-5´-chloro-
2´-hydroxyacetophenone as a starting material. The chloride could be removed under the 
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catalytic hydrogenation step in the synthesis, since the dehalogenated derivative was 
observed as a byproduct in that particular step during the synthesis. 
 
Preliminary in vivo experiments (not shown) with 80 in IEC-6 and NIH 3T3-cells (rat 
epithelial and mouse fibroblasts cell lines, respectively) showed reduced phosphorylation 
of ERK1/ERK2, as monitored with phospho-specific antibody to the activation loop of 
ERK1/2. Interestingly, the results also demonstrated that 80 displays a slightly less active 
profile in comparison with the nanomolar modulator CI-1040 (PD184352) (Figure 32). 
 
Table 7. In vitro activity of PD98059,204 80, 81 and 85 toward MEK1. 
 
Compound Structure 
IC50 (µM) 
MEK1 
PD98059 
 
10.0 
80 
 
 
1.9 
81 
 
6.4 
85 
 
3.6 
 
5.4  CONCLUSIONS 
In summary, this chapter describes the design and synthesis of chromone-based ATP-
competitive p38 inhibitors and allosteric non-ATP-competitive MEK1 modulators. 
Molecular docking was used for the design in order to explore suitable substitution 
patterns on the chromone scaffold to obtain selective and highly active inhibitors or 
modulators against p38 and MEK1. The biological evaluation reveled that several of the 
synthesized p38 inhibitors exhibit a strong inhibitory activity toward the p38 MAP 
kinase (e.g., 59, IC50 17 nM). Among them, 59 and 63 were shown to be selective 
inhibitors of the p38 and p38 isoforms, and it was also revealed that 63 inhibits p38 
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kinase signaling in human cancer cells. Furthermore, the synthesized allosteric MEK1 
modulators showed moderate activities with IC50 values in the micromolar range (IC50 
1.9-6.4 M), which are comparable with the known allosteric MEK1 modulator PD98059 
(IC50 10 M). The modeling study suggested that substituents in the 8-position on the 
chromone structure could fit into a hydrophobic cavity in MEK1 that connects the 
allosteric pocket with the ATP-binding site. Moreover, an ethoxy group in the 3´-position 
could utilize the area in the allosteric pocket more efficiently than a methoxy group. 
However, more studies around the structure-activity relationship need to be done. This 
could e.g. include the synthesis of a second generation of chromone-based allosteric 
MEK1 modulators with various substituents in the 8-position. However, if this should be 
done we need to optimize the yields in some of the reaction steps. 
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6. Concluding Remarks and Future Perspectives 
 
 
 
This thesis describes the usefulness of chalcone and chromone derivatives as valuable 
agents for various applications in the field of medicinal chemistry. The studies show that 
they are particularly useful as small molecular inhibitors targeting proteins associated with 
cancer pathogenesis and as fluorophores for live-cell imaging. Through efficient synthetic 
methods based on scaffold methodology we have prepared several series of differently 
functionalized chromone derivatives that can be modified to generate compounds that 
possess different biological activities. However, there are still interesting aspects to 
explore within the various projects described in this thesis, and some of these aspects are 
outlined below. 
 
 Further studies of 3-hydroxychromones as potential fluorophores for live-cell 
imaging could involve covalent probing of biological active compounds such as 
proteins or small molecule inhibitors. The labeled conjugates could further be used 
as biological tools in fluorescent microscopy of living cells for the investigation of 
cellular pathways, uptake, and distribution. Moreover, tuning the fluorescence 
properties via structural modifications on the chromone scaffold could optimize 
the absorption and emission toward longer wavelengths, preferable for cell 
viability. 
 
 In order to further establish the structure-activity relationship for chalcones and 
related dienones that interfere with tubulin assembly, larger series of structurally 
diverse derivatives needs to be synthesized. This could also include investigations 
around what kind of structural modifications that are responsible for the 
generation of stabilizing vs. destabilizing activities.  
 
 Our development towards chromone-based kinase inhibitors/modulators could be 
extended with larger series of derivatives in order to understand the structure-
activity relationship and to improve the inhibitory activities. However, extensive 
optimization of several reaction steps for the synthesis of the chromone-based 
MEK1 modulators needs to be done before such a study can begin. Future 
investigations could also involve attempts to develop isoform-specific p38 or 
MEK1 inhibitors/modulators or the design of MEK1 inhibitors that utilize both 
the allosteric pocket and the ATP-binding site.   
 
70 
 
 Since this thesis present chromone derivatives with fluorescence or bioactive 
properties in would be interesting to combine these features. For example to 
design fluorescent chromone-based kinase inhibitors and follow their uptake and 
accumulation in living cells by using fluorescence microscopy. Such studies could 
provide valuable information of cancer-specific pathways in living organisms.  
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A.  ESSENTIAL AMINO ACIDS FOUND IN PROTEINS 
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B. EXPERIMENTAL PROCEDURES FOR COMPOUNDS NOT INCLUDED  
IN PAPERS I-IV 
 
General All reagents and solvents were of analysis or synthesis grade. 1H NMR-spectra 
were recorded on a JEOL JNM-EX 400-spectrometer at 400 MHz in CDCl3. Chemical 
shifts are reported in ppm with the solvent residual peak as reference; CDCl3 (δH 7.26). 
The reactions were monitored by thin-layer chromatography (TLC), on silica plated (Silica 
gel 60 F254, E. Merck) aluminum sheets, detecting spots by UV (254 and 365 nm). Flash 
chromatography was performed using a Biotage SP4 Flash instrument with prepacked 
columns. Microwave reactions were carried out in a Biotage Initiator instrument with a 
fixed hold time using capped vials.  
 
 
(E)-1-(2-Hydroxyphenyl)-3-phenylprop-2-en-1-one (39). KOH (3.7 
g, 66.0 mmol) was added to a stirred solution of 2´-
hydroxyacetophenone 36 (3.0 g, 22.0 mmol) and benzaldehyde (2.46 ml, 
24.2 mmol) in EtOH (150 mL). The mixture was heated at 50 °C for 3 h and was then 
stirred at room temperature overnight. The dark red solution was acidified with HCl (aq., 
1M) to yield a yellow precipitate, which was filtered off and washed with water. The 
precipitate was recrystallized from EtOH to afford 39 (1.9 g, 67%) as yellow crystals. 1H 
NMR (CDCl3) δ 6.92-6.99 (m, 1H), 7.04 (dd, J = 1.1, 8.4 Hz, 1H), 7.42-7.54 (m, 4H), 
7.63-7.69 (m, 3H), 7.93-7.99 (m, 2H), 12.84 (s, 1H). 
 
2-Phenylchromone (40). Iodine (226 mg, 0.89 mmol) was added to a 
solution of 39 (100 mg, 0.45 mmol) in EtOH (5 mL) and the suspension 
was heated in a microwave cavity at 150 °C for 160 min. The mixture was 
quenched with saturated Na2S2O3 (aq), extracted with dichloromethane (3 
 10 mL), dried over MgSO4 and concentrated. The product 40 (99 mg, 99%) was 
obtained as off-white crystals. 1H NMR (CDCl3) δ 6.84 (s, 1H), 7.39-7.46 (m, 1H), 7.50-
7.60 (m, 4H), 7.67-7.74 (m, 1H), 7.91-7.96 (m, 2H), 8.24 (dd, J = 1.5, 8.1 Hz, 1H). 
 
3-Bromo-2-phenylchromone (49). NBS (319 mg, 1.79 mmol) was added 
to a solution of 40 (362 mg, 1.63 mmol) in DMF (16 mL). The reaction 
mixture was heated in a microwave cavity at 60 °C for 30 min. The 
reaction mixture was quenched with Na2S2O3 (aq., 10%) and the aqueous 
phase was extracted with ethyl acetate (3  20 mL). The combined organic phases were 
washed with brine (60 mL), dried over MgSO4 and concentrated. The crude was purified 
by flash chromatography (heptane/ethyl acetate, gradient 20  40% ethyl acetate) to 
afford 49 (256 mg, 52%) as an off-white powder. 1H NMR (CDCl3) δ 7.45-7.58 (m, 5H), 
7.70-7.76 (m, 1H), 7.84-7.89 (m, 2H), 8.31 (dd, J = 1.8, 8.1 Hz, 1H). 
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3-Iodo-2-phenylchromone (50). Iodine (42 mg, 0.17 mmol) and CAN 
(79 mg, 0.14 mmol) were added to a solution of 40 (32 mg, 0.14 mmol) in 
acetonitrile (2 mL). The mixture was heated in a microwave cavity at 65°C 
for 30 min, 100 °C for 15 min and 130 °C for 15 min. The reaction 
mixture was quenched with Na2S2O3 (aq., 10%), extracted with dichloromethane (3  5 
mL), dried over MgSO4, and concentrated. The crude was purified by flash 
chromatography (heptane/ethyl acetate, gradient 20  40% ethyl acetate) to afford 50 
(34 mg, 67%) as a white solid. 1H NMR (CDCl3) δ 7.43-7.48 (m, 5H), 7.69-7.83 (m, 3H), 
8.30 (dd, J = 1.7, 8.0 Hz, 1H). 
 
General procedure for the synthesis of 3-arylflavones (55-56). The appropriate 
boronic acid (4 equiv) was added to a suspension of 49 (1 equiv) in PEG-400 (20 g/mmol 
aryl bromide) followed by the addition of Pd(OAc)2 (0.2 equiv) and K2CO3 (2 equiv). The 
reaction mixture was heated in a microwave cavity at 60 °C for 30-60 min. The reaction 
mixture was poured over brine (5 mL), extracted with diethyl ether (3  5 mL) and 
washed with brine. The combined organic phases were dried over MgSO4, filtered 
through Celite and concentrated. The crude product was purified by flash 
chromatography. 
 
2,3-Diphenylchromone (55). The title compound was synthesized 
according to the general procedure. Compound 49 (59 mg, 0.20 mmol) 
and phenyl boronic acid (96 mg, 0.78 mmol) gave 55 (49 mg, 84%) as an 
off-white solid. The product was purified by flash chromatography using 
heptane/ethyl acetate (9:1). 1H NMR (CDCl3) δ 7.20-7.58 (m, 12H), 7.68-7.74 (m, 1H), 
8.28-8.33 (m, 1H). 
 
3-(4-Fluorophenyl)-2-phenylchromone (56). The title compound was 
synthesized according to the general procedure. Compound 49 (40 mg, 
0.13 mmol) and 4-fluorophenyl boronic acid (74 mg, 0.53 mmol) gave 
56 (24 mg, 53%) as an off-white solid. The product was purified by flash 
chromatography using heptane/ethyl acetate (gradient 10  20% ethyl acetate). 1H NMR 
(CDCl3) δ 6.96-7.04 (m, 2H), 7.15-7.48 (m, 8H), 7.52-7.57 (m, 1H), 7.68-7.75 (m, 1H), 
8.29 (dd, J = 1.8, 8.1 Hz, 1H). 
